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Spinal cord injury (SCI) is a devastating condition to individuals, families, and society. Oligodendrocyte loss and demyelination
contribute as major pathological processes of secondary damages after injury. Oligodendrocyte precursor cells (OPCs), a
subpopulation that accounts for 5 to 8% of cells within the central nervous system, are potential sources of oligodendrocyte
replacement after SCI. OPCs react rapidly to injuries, proliferate at a high rate, and can differentiate into myelinating
oligodendrocytes. However, posttraumatic endogenous remyelination is rarely complete, and a better understanding of OPCs’
characteristics and their manipulations is critical to the development of novel therapies. In this review, we summarize known
characteristics of OPCs and relevant regulative factors in both health and demyelinating disorders including SCI.More importantly,
we highlight current evidence on post-SCI OPCs transplantation as a potential treatment option as well as the impediments against
regeneration. Our aim is to shed lights on important knowledge gaps and to provoke thoughts for further researches and the
development of therapeutic strategies.
1. Introduction
Spinal cord injury (SCI) is a catastrophic event that com-
monly results in axonal injuries and deaths of neurons and
glial cells. Subsequent secondary injuries that consist of
uncontrolled inflammation, excitotoxicity, edema, ischemia,
and chronic demyelination can lead to additional damages,
while the formation of glial scars also prohibits axonal
regeneration [1] (Figure 1). SCI causes disturbances to normal
sensory, motor, or autonomic functions and can significantly
affect patients’ physical, mental, and social well-being [2,
3]. Current therapies mainly rely on early operations for
mechanical decompression, symptomatic relief, supportive
care, and rehabilitation. With the development of stem cell
technologies, cell-based transplantation is now thought to
be a promising therapeutic approach for SCI. In fact, an
autologous bone marrow stem cell transplantation approach
is already undergoing a phase II clinical trial (NCT02009124,
https://clinicaltrials.gov/), while a neural stem cell transplan-
tation study is currently in phase I/II trial (NCT02326662,
https://clinicaltrials.gov/).Though exciting, their clinical util-
ities are still far frombeing clear partially due to unclear safety
issues such as teratoma formation.
A potentially useful cell source for post-SCI transplan-
tation is oligodendrocyte precursor cells (OPCs). The lat-
ter are the major source of oligodendrocytes responsible
for myelination within the central nervous system (CNS).
The proliferation, migration, and differentiation of OPCs
are sophisticatedly regulated by numerous factors including
neuronal- or axonal-glial neurotransmitters, growth factors,
neurotrophins, and transcription factors. The majority of
OPCs are quiescent with limited self-division under normal
circumstances, but they may respond rapidly to injuries and,
in particular, demyelination. However, their rescuing effects
are commonly hindered by the hostile microenvironment
at the injury sites, leading to incomplete remyelination and
clinical recovery. Therefore, finding ways to boost endoge-
nous OPCs by enhancing the positive regulatory factors
while attenuating negative ones has been an area of intense
investigations in neurotrauma research.
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Figure 1: The major pathophysiological phases after spinal cord injuries. BSCB: blood-spinal cord barrier; OLs: oligodendrocytes; ECM:
extracelluar matrix; CSPGs: chondroitin sulfate proteoglycans.
This review will first summarize known characteristics
of OPCs and then focus on the current understandings
about the potential roles of OPCs in SCI, in particular, their
effects on remyelination and glial scars formation. Recent
progress in OPCs transplantation research and associated
concerns will be discussed as well. Our aim is to shed lights
on important knowledge gaps and to provoke thoughts for
further researches and therapeutic treatment strategies.
2. Oligodendrocytes Loss and Demyelination
after Spinal Cord Injury
The myelin sheaths are essential for saltatory signal con-
duction and tropic support to maintain axonal integrity [4].
Unfortunately, mature oligodendrocytes, the only myelin-
forming cells within the CNS, are highly susceptible to
damages [5]. Grossman et al. observed an acute loss of
oligodendrocytes, along with neuronal death, as early as 15
minutes after injury in a rat spinal contusion model [6] and
which might last for 3 to 7 days [7]. In an observational study
with a 450-day follow-up after contusive SCI in adult rats,
the extent of demyelination significantly dropped within one
week after injury, followed by fluctuations at a lower level for
about 70 days, and then increased steeply during the rest of
the observation period. The findings suggested a chronic on-
going process of aggravated demyelination [8].
The underlying mechanisms are far from clear, how-
ever. Besides the initial acute insults, both necrosis and
apoptosis of oligodendrocytes have been observed in the
chronic phase of injury [9–12]. Numerous factors may con-
tribute to this process including the overabundant release of
proinflammatory cytokines such as tumor necrosis factor-𝛼
(TNF-𝛼) and interleukin-1𝛽 (IL-1𝛽), uncontrolled oxidative
stress, and ischemia as well as glutamate- and ATP-mediated
excitotoxicity [12, 13]. It is worth pointing out that though
autophagy, another type of cell death, has been shown to
cause oligodendrocytes death [14, 15], its positive and nega-
tive impacts remain controversial. Smith et al. demonstrated
that autophagy did not increase oligodendrocyte loss in
the spinal cord upon terminal deoxynucleotidyl transferase
dUTP nick end labeling (TUNEL) assay and caspase-3
immunostaining; instead, autophagy was found to promote
myelin development [16].
Historically, it was thought that oligodendrocytes and
intact myelin sheath were primarily responsible for the facil-
itation of neuronal signal conduction only. The potential role
of oligodendrocytes in preserving the integrity and survival
of axons was not realized until Griffiths and McCulloch
reported acute retraction of some lateral loops fromparanode
at 1.5 hours after injury due to oligodendrocytes loss [17].
Given the fact that each oligodendrocyte is responsible for
30–80 distinct axons, it could be expected that extensive
demyelination may occur even after the collapse of only
a single oligodendrocyte [18, 19]. Indeed, transgenic mice
with mutated myelin proteins such as myelin proteolipid
protein (PLP) and DM-20 were found to show overt axonal
swelling and degeneration [20]. Similar observations were
also made in mice harboring mutations of other mature-
oligodendrocyte-related proteins or genes [21–23]. Together,
these findings have given rise to the current concept that
axonal integrity relies heavily on oligodendrocyte support
and that oligodendrocyte loss would result in axonal degen-
eration.
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It is known that axons of cortical neuron may project
as far as 100 cm within the corticospinal tract [24]. Besides,
myelin sheaths essentially shield axons from their surround-
ings and limit access to extracellular metabolites. These raise
concerns about metabolic homoeostasis and energy supply
to the axons. In this regard, oligodendrocytes have been
shown to produce lactate, an alternative energy source for
axons within the CNS [25–27]. Reducing MCT-1, one of the
monocarboxylate transporters (MCTs) in oligodendrocytes,
resulted in severe axonal swelling, indicative of the important
role of oligodendrocyte-derived lactate [28]. Furthermore,
myelinating oligodendrocytes were able to synthesize and
deliver ATP to axons through connexons, a kind of gap
junctions protein [29, 30]. This increases the conduction
speed of action potentials [31]. Other factors responsible
for axonal development and stabilization include 2󸀠,3󸀠-cyclic
nucleotide phosphodiesterase 1 (CNP-1) gene [32] and per-
oxisomal targeting signal 1 receptor (PEX5) gene [33]. These
findings suggest that, in addition to their predominant
functions in nerve conduction, oligodendrocytes may also
labor as mechanical and trophic supports to axons [24, 26].
As naked or demyelinated axons are more vulnerable to
injuries, it is reasonable to expect that, after injury, efficient
remyelination is critical not only for cellular replacement
but also neuron-glial cross talk reconstruction and neuronal
function recovery.
3. Oligodendrocyte Precursor Cells and Their
Characteristics
3.1. Multipotency of Oligodendrocyte Precursor Cells. Vaughn
and Peters first discovered a type of small and irregularly
shaped cells with stout processes that were without astrocytes
or oligodendrocytes characteristics in adult, embryonic, and
perinatal rat optic nerves [49]. On autoradiography, these
cells reacted to Wallerian degeneration and represented 85–
90% of proliferating cells after degeneration despite the
fact that they only accounted for ∼5% of all glia under
normal conditions [50, 51]. These cells were initially termed
“oligodendrocyte-type-2 astrocyte (O-2A) progenitor cells”
due to their potencies for developing into either oligoden-
drocytes or type-2 astrocytes under specific conditions [52–
54]. More recently, these cells were renamed “oligodendro-
cyte precursor cells (OPCs)” because of their predominant
function of regenerating oligodendrocytes in demyelinating
conditions [55]. OPCs are found in both white and gray mat-
ters within the CNS though abundantly so in the former [56].
Morphologically, OPCs have small cell bodies and multiple
processes and may adopt a bipolar or tripolar shape [57].
Interestingly, the terminology of OPCs has received fur-
ther challenges because of recent discoveries of their abilities
to give rise to neurons. Purified OPCs from postnatal day 6
rat optic nerve have been shown to revert back to multiple
CNS stem cells, which could in turn give rise to neurons
and oligodendrocytes as well type-1 and type-2 astrocytes
[58]. Although these findings were initially challenged on the
ground of experimental techniques [59], they were subse-
quently confirmed both in vitro and in vivo [60, 61]. Guo et al.
detected low expression of doublecortin (DCX), a marker for
migrating and immature neurons, in a population of cells
with negative HuC/D signals (exclusively presented in neu-
rons) but positive PDGFR-𝛼 and Sox10 signals, both of which
are determinating markers of final oligodendrocyte matu-
ration [62]. These DCX+/PDGFR-𝛼+/HuCD- cells raised
thoughts about the idea that at least some endogenous OPCs
do have characteristics of neurons. Indeed, using PDGFR-𝛼
promoter-driven Cre, scientists were able to induce neuronal
formation from OPCs in adult piriform cortex [63]. Similar
findings were also observed in vivowithin adult rat neocortex
[64], neonatal mouse forebrain [65], and postnatal cerebral
cortex [62].
3.2. OPCs as Postsynaptic Neuronal Regulatory Targets. The
conventional dogma that classic chemical synapses exist
exclusively as neuron-neuron connections was challenged by
the discovery of functional glutamatergic synapses between
OPCs and axons [66–69].The latter would includeN-methyl-
D-aspartate receptor (NMDAR), alpha-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid receptor (AMPAR), and
kainite receptors. On oligodendrocytes, these receptors are
activated by glutamate released by either neurons or axons,
which increases intracellular Ca2+ level through stimula-
tion of voltage-dependent Ca2+ channels or the reversal of
Na+/Ca2+-exchangers. Li et al. demonstrated that NMDA
would promote OPCs maturation and myelination in dorsal
root ganglions- (DRGs-) OPCs coculture system in vitro [69].
Moreover, glutamate released by cultured cortical neurons
could promote OPCs migration by stimulating NMDAR; T
lymphoma invasion and metastasis 1 (Tiam1), a Rac1 guanine
nucleotide exchange factor (Rac1-GEF) that is coexpressed
and interacts with NMDAR in OPCs, would antagonize
NMDAR and suppress migration [70].
Remyelination was found to be significantly delayed
by the NMDAR specific antagonist MK801 in an in vivo
cuprizone demyelination model, suggesting that NMDAR is
essential for the entire OPCs-initiated remyelination process
[69]. Others such as AMPA-type glutamate receptors may
also participate in neuron- and axon-OPCs connections.
AMPAR activation appeared to be essential for OPCs mor-
phological alterations rather than proliferation and differen-
tiation during myelination [71]. AMPAR blockade resulted
in the inhibition of OPCs morphological development while
promoting proliferation and differentiation [72]. Interest-
ingly, a recent study also demonstrated that the degree of
OPCs-neuron contacts actually differed between demyelina-
tion and remyelination phase in that synapses would only
form during remyelination upon sufficient proliferation after
demyelination [73]. These findings were derived from a
lysolecithin- (LPC-) induced demyelination model, however,
and whether the same would apply in SCI remains to be
tested. It is plausible that OPCs may lack glutamatergic
synapses immediately after injury in order to promote self-
proliferation, and synaptic inputs would only develop during
the migration and maturation stages in preparation for fur-
ther remyelination. And to accomplish final myelin sheaths
4 BioMed Research International
formation, a subsequent regain of AMPA synapses may be
required for correct morphological development.
More than 90% of synaptic currents in OPCs in the
neocortex are evoked by gamma-aminobutyric acid-ergic
(GABAergic) synapse [74], and GABAergic connections
between neuronal axon and OPCs are abundant [75, 76].
As in the case of glutamatergic receptors, activation of
GABA-𝛼 receptors may trigger Ca2+ influx via Na+/Ca2+
exchangers and promote OPCs migration [77]. In light of
this evidence, it is highly likely that Ca2+ influx triggered
by either glutamatergic or GABAergic synapses is essential
for OPCs migration by means of cytoskeletal reorgani-
zation, cell mobility, membrane traffic, and cell adhesion
and deadhesion [78]. On the other hand, a more complex
case is found in a cerebellar diffuse white matter injury
model in which hypoxia-induced loss of GABA-𝛼 receptor-
mediated synaptic input to OPCs significantly suppressed
OPCs maturation while promoting proliferation [79]. In this
regard, it seems that depolarization or hyperpolarization of
GABAergic synapses contributes to different aspects of OPCs
regulation. The expression of GABA-𝛽 receptors on OPCs
and their physiological functions is incompletely understood.
It is known that both GABA-𝛽1 and GABA-𝛽2 subunits are
localized onOPCs and that stimulatingGABA-𝛽 receptors by
baclofen, a selective agonist, substantially increasesmigration
and proliferation, providing evidence for a functional role
of GABA-𝛽 receptors in oligodendrocyte development [80].
The temporal-spacial alteration of either type of GABAergic
synapses after CNS injury and the effect on OPCs and
posttraumatic remyelination are not yet clear.
Purinergic receptors, including P1 receptors (alternatively
termed as adenosine receptors), metabotropic P2Y receptors,
and ionotropic P2X receptors, are widely distributed in
neurons and glial cells. As the breakdown product of ATP,
adenosine is the main ligand targeting four subtypes of
adenosine receptors (A1, A2a, A2b, and A3 receptors), all
of which have been identified in OPCs [81]. Activation of
adenosine receptors evokes the alteration of Ca2+ signals via
G-protein coupled receptors in OPCs and regulates their
differentiation and myelination. Particularly, activation of A1
receptor may be indispensable in recruiting OPCs to sites of
injury where remyelination occurs [82]. Contrarily, A2 recep-
tors may possibly act in a different way since they simulate
cyclic adenosine monophosphate (cAMP) via Gs receptors
rather than Gi receptors as for A1 receptors. Indeed, selective
A2a receptor activation may suppress OPCs proliferation in
vitro through the inhibition of K+ currents [83].Though little
knowledge is provided yet, it is highly believed that figuring
out the effects of A2b receptors upon OPCs may offer more
information in regulating them under pathological circum-
stances since it is shown that higher concentration of adeno-
sine is needed for activation of A2b receptors, which probably
can be detected in trauma, hypoxia, or ischemia [84].
Adenine (i.e., ATP and ADP) and uracil nucleotides (i.e.,
UTP and UDP) activate P2 receptors rather than adenosine
receptors. Activating P2X7, the only functionally active P2X
receptor in OPCS, results in a sustained influx of Ca2+ and
regulates pathological responses ofOPCs [85].There is strong
evidence that blocking P2X7 can have a neuroprotective
effect against ATP-induced oligodendrocytes-toxicity [86]
and that downregulation of P2X7 receptors expression may
occur after hypoxic ischemic injury [87].Whilemetabotropic
P2Y receptors may or may not be directly related to cell
viability, their involvements in promoting OPCs migration
[88] and prohibiting proliferation [85] have been reported.
The functions of other P2Y receptors subtypes such as P2Y2,
P2Y4, and P2Y12 in OCPs and SCI are even less well
understood and deserve further investigations [89, 90].
The expression of muscarinic acetylcholine (mACh)
receptors, a subtype of cholinergic receptors, has been suc-
cessfully identified on OPCs [91]. Activation of mACh may
rescue OPCs from growth factor deprivation [92]. Alter-
natively, mACh receptors activation significantly promotes
OPCs proliferation while prohibiting their maturation [93].
Conversely, antimuscarinic adjunct therapy was found to
offer a prodifferentiative effect in human OPCs in vitro.
Enhanced functional recoveries were also shown with sys-
temic treatment with mACh receptors antagonist following
transplantation of human OPCs into hypomyelinated rats
[94]. The role of nicotinic acetylcholine (nACh) receptors,
which are expressed on OPCs also, is not yet known [95, 96].
3.3. Regulation of Oligodendrocyte Precursor Cells. OPCs
functions are intricately modulated by a complex network
of growth factors, cytokines and chemokines, neurotrophins,
and transcription factors, all of which would affect the
remyelinating process in SCI.
Growth Factors. Platelet-derived growth factor-A (PDGF-
A) and fibroblast growth factor-2 (FGF-2) are two classic
factors affecting oligodendrocyte lineage development. Sta-
ble expression of PDGFR-𝛼 in OPCs and the mitogenic
effect of PDGF-A, a ligand to PDGFR-𝛼, in oligodendrocyte
lineage have been long established [57]. OPCs in white
matter respond to PDGF-A stimulation via Wnt/𝛽-catenin
and phosphatidylinositol 3-kinase pathways by increasing
proliferation rate [97]. The evidence that PDGF-A stimulus
may accelerate the migration of OPCs by activating ERK
pathway gives thought to its potential prorecruitment role
on OPCs after SCI [98]. FGF-2 is another strong mitogen
to OPCs. Direct intraventricular injection of FGF-2 after
subventricular zone dissection injury not only enhanced
the generation of OPCs but also promoted the differenti-
ation of oligodendrocytes from OPCs [99]. In agreement
with this, a double knockout of FGF receptors 1 and 2
significantly impacted on the differentiation of OPCs and
hindered myelin sheaths formation in a chronic cuprizone-
induced demyelinationmodel but not in acute demyelination
in the same study [100]. Interestingly, proliferation of OPCs
can be induced in culture of conditioned medium from
B104 neuroblastoma cells, possibly due to the coexistence
and synergy of PDGF-A and FGF-2 [101]. Other growth
factors include insulin-like growth factor (IGF), which has
synergic functions with PDGF and FGF through common
downstream messengers like PI3K/AKT and ERK pathways.
Ciliary neurotrophic factor (CNTF), a pleiotropic
cytokine within the IL-6 family, has been shown to promote
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spinal cord-derived OPCs survival and differentiation in
culture as well as endogenous OPCs migration in an acute
demyelination model [102, 103]. In the situation of SCI, a
chronic and continua increase of CNTF level was observed
in contusive spinal cord tissues, especially along the border
of injury site where posttraumatic oligodendrogenesis
was severe [104]. The idea of CNTF being involved in the
regulation of OPCs after SCI is supported by a recent study
showing enhanced remyelination and functional recovery
after transplantation of CNTF-expressing adult OPCs into
contused spinal cord [34].
Neurotrophins. Neurotrophins are responsible for the regu-
lation of survival and development of neural cells including
neurons and progenitor cells. Direct promyelinating effect
of brain-derived neurotrophic factor (BDNF) via activation
of TrkB receptors has been demonstrated in dorsal root
ganglions- (DRGs-) OPCs coculture system [105]. Consis-
tently, deletion of TrkB receptors in mice reduced thickness
ofmyelin sheath but would have no effect on oligodendrocyte
maturation or the number of myelinated axons. Surprisingly,
knockout of TrkB receptors actually led to a significant
increase in the density ofOPCs, suggesting that the regulatory
effects of BDNF via TrkB receptors may be phase-dependent
[106]. Neurotrophin-3 (NT-3) is another neurotrophin that
has a positive role in inducing survival and proliferation of
OPCs [107]. Both BDNF and NT-3 expressions increase after
SCI in mammals [108, 109], and additional NT-3, alone or
combined with sonic hedgehog, could increase the number
of OPCs and enhance remyelination after SCI [110].
Chemokines and Cytokines. Chemokines are key players in
the immunological and hematological systems. They are
also coexpressed with neurotransmitters such as choline
and dopamine in specific regions of the brain where they
serve specific functions [111, 112]. Though the expression of
a number of chemokines would alter after SCI, not all are
responsible for OPCs modulation. For example, CCL2 (also
known as MCP-1) expression is elevated during the acute
phase after spinal cord damaging and its inhibition would
attenuate secondary SCI [113]; it does not affect proliferation
andmyelination ofOPCs [114]. In contrast, CXCL12 (SDF-1𝛼)
and its receptor CXCR4 would promote OPCs proliferation
and myelin sheath formation in a dose-dependent matter
[114–116]. CXCL1 (GPO-𝛼) and its receptor CXCR2 may also
take part in the regulation of OPCs survival in pathological
states. Enrichment of CXCL1 ameliorates OPCs death from
inflammation cascade, which is a major component of sec-
ondary injury after CNS trauma [117, 118].
It has been demonstrated that the synthesis of several
cytokines such as leukemia inhibitory factor (LIF) is upreg-
ulated after SCI [119]. LIF is known to promote oligoden-
drocyte lineage development [120] and protect OPCs after
demyelinating injuries and ischemic trauma [121, 122]. Also,
transportation of LIF through impaired spinal cord-blood
barrier has been observed after SCI [123]. Interferon-gamma
(IFN-𝛾) also exerts interesting dual effects on OPCs in a
concentration-dependent manner; it maintains OPCs in the
cell cycle at low level of expression, whilst higher levels would
cause demyelination [124]. IL-17A is another new candidate
that can induce OPCs to exit the cell cycle and commence
differentiation into mature oligodendrocytes by activating
ERK1/2 pathways in demyelinating pathologies [125]. These
effects may occur in conjunction with IL-1𝛽, which is known
to protect OPCs and promote their differentiation. But unlike
IL-17A, IL-1𝛽 arrests OPCs in the cell cycle and hinders their
mitosis [126]. It would be interesting to study the combined
effects of IL-17A and IL-1𝛽 upregulation after SCI [119].
Transcription Factors.A vast body of literatures has described
the transcriptional networks that regulateOPCs, one ofwhich
is the basic helix-loop-helix (bHLH) family. Of particular
interest is the significant role played by oligodendrocyte
transcription factors 1 (OLIG1) and OLIG2, both being
oligodendrocyte-specific genes [127, 128]. Double-mutant
OLIG1 and OLIG2 would eliminate the formation of OPCs
and the genesis of motor-neurons and oligodendrocytes
[129], while transient expression of OLIG1 would induce
the formation of OPCs from neural stem cells [130]. For
remyelination, a series of loss- and gain-of function in
vitro studies have demonstrated the comparatively more
predominant role of OLIG2 [131–133]. Overexpression of
OLIG2 in transgenicmicemay lead to precociousmyelination
throughout the CNS aswell as enhancedOPCsmigration and
remyelination [134]. OLIG1 and OLIG2 also interact. While
OLIG2 expression is upregulated in contused spinal cord
[135], its solo overexpressionwould result in tumorous cell
growth. Interestingly, such tumorigenesis is absent under the
situation of simultaneous expressions of OLIG1 and OLIG2,
indicating a directly restrictive and mutually modulatory
function between them [136]. Compared with OLIG2, OLIG1
plays a secondary and nonessential role in oligodendrogen-
esis as OLIG1 null mice lines have shown only a mild delay
in oligodendrocyte differentiation and maturation without
long-term effect [137].
OLIGs are modulated by other transcription factors
such as inhibitor of DNA-binding protein 4 (ID4) and its
companion ID2, both of which act as overt transcriptional
repressors upon OPCs differentiation and maturation by
sequestrating OLIG1 and OLIG2 and preventing them from
binding consensus DNA domains [138, 139]. This indicates a
potential modulating role of IDs on OPCs in SCI. Indeed,
electroacupuncture treatment after compressive spinal cord
injury was found to protect myelin sheath breakdown and
increase OPCs proliferation by promoting OLIG2 but atten-
uating ID2 expression [140].
The highmobility group (HMG) family, another group of
transcriptional factors, also modulates OPCs. In particular,
SOX5 and SOX6 from D subgroup of HMG are found in
OPCs, and they repress the terminal maturation of OPCs
and hinder their migration [141]. In OPCs, SOX6 expression
requires the consistent presence of SOX8 and SOX9, which
guarantee the generation of OPCs in conjunctionwith SOX10
[141, 142]. The latter is crucial for the terminal differentiation
of OPCs since ablation of SOX10 would lead to an altered
migration pattern and reduced quantity of OPCs due to
enhanced apoptosis [142]. SOX10 may also act as a regulating
target and mediator of OLIG1 and OLIG2 during OPCs
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maturation [136]. The likely synergistic relationship between
SOX10, OLIG, andMYRF further complicates the picture and
calls for more detailed posttranscriptional studies [143, 144].
Current evidence also suggests the positive participa-
tion of ZFP191 and ZFP488, two members of zinc fin-
ger transcription factors, in OPC regulations. Mutation of
ZFP191 in C3H/HeJ genetic mice would lead to significant
hypomyelination with preserved process-outreaching pro-
genitors, indicating that ZFP191 may have a stage-specific
action. ZFP488 is an oligodendrocyte-specific regulator. Its
overexpression would promote oligodendrocyte precursor
formation in cooperation with OLIG2 [145]. Of particular
interest is myelin transcription factor 1 (MYT1) which is
upregulated in the injured spinal cord [146]. In light of the
evidence that MYT1 is crucial for progenitor proliferation
and differentiation [147], it is possible that MYT1 may
contribute to the modulation of OPCs in SCI. Many other
transcription factors such as MASH1 (alternatively known as
ASCL1) [148], NKX family [149], and Yin Yang 1 (YY1) [150]
may similarly regulate oligodendrocytes generation although
concrete evidence is still lacking.
4. Roles of Oligodendrocyte Precursor Cells
after Spinal Cord Injuries
4.1. Alterations after Spinal Cord Injuries. OPCs respond to
SCI rapidly by altering their morphologies and accelerating
mitosis [151, 152]. Overall, the proliferation rate of OPCs
would significantly increase by the end of the first day after
injury and remain elevated in the following week. Cells
number would remain high for a whole month. Two different
subtypes of OPCs may be identified within and around the
injury site [153]. Round-shapedOPCswith highNG2 staining
and short thick processes were found along the injury lesions;
this contrasts with OPCs with multiple processes seen 200–
300 um away from the lesion. In general, OPCs positively
stained for NG2 and BrdU antibodies were found throughout
the impact site and the surrounding spared areas in the first
week after injury [154]. Elevated proliferation continued for
two weeks, followed by a decline within the epicenter and
rostral sections but not the caudal parts. Another time-course
study described a more rapidly upregulated proliferation by
day 2 that peaked by the 4th day and then declined by week
1 [155]. A closer look at the temporal-spatial pattern showed
that, instead of the epicenter, most BrdU+ OPCs were in fact
concentrated within 1.5mm rostral to the injury site 3 days
after SCI [7, 156]; the number of cells labeled with NG2/Ki67
would drop within 4 hours, indicating a local toxic effect after
injury [157].
There is hitherto scanty information on the mobility
of OPCs after SCI although they are generally thought to
migrate at a slower rate than their precursor stem cells
[158]. Whether proliferative OPCs around the injury site are
activated in situ or derived from immigrating cells remains
unknown. Carroll et al. studied experimental demyelinat-
ing optic nerve lesions and reported a centripetal migra-
tion of cells towards the lesion by day four. Though not
firmly identified as OPCs, these cells did differentiate into
oligodendrocytes during and after migration [159], and it is
possible that the same may occur in SCI. In another study
using a spinal contusion injury model, treatment with the
enzyme chondroitinase ABC, which removed the inhibitory
effects of chondroitin sulfate proteoglycans (CSPGs), could
significantly enhance the quantity ofOPCs 2-fold [160].Using
double-staining techniques, the authors further demon-
strated that none of the OPCs were positive for BrdU/Olig1 or
Ki67/Olig1, suggesting that the increase of OPCs number was
primarily due to migration rather than in situ proliferation.
4.2. Remyelination by Endogenous Oligodendrocytes Precursor
Cells. Identifying the exact cell type responsible for remyeli-
nation in diseases is critical for the development of ther-
apeutic interventions. Self-mitosis and replacement for the
damaged cells are considered as a direct and plausible way of
healing and recovery after injuries. As a consequence, mature
oligodendrocytes, being themyelin-forming cells in the CNS,
were initially thought to be responsible for posttraumatic
remyelination [161].However, this postulationwas challenged
by the evidence that terminally differentiated oligodendro-
cytes would represent no more than one-fourth of the total
BrdU+ cells in spinal cord tissue following contusive injury
[156], and surviving oligodendrocytes after injuries would
possess extremely limited abilities to divide [162].
An alternative hypothesis is that OPCs may be responsi-
ble for the generation of myelinating cells and remyelination
instead [152, 154, 163]. Watanabe et al. found a robust prolif-
eration of OPCs during the first week after chemical-induced
demyelination, followed by a steep decline of OPCs with an
increase in the number of mature oligodendrocytes [164].
More importantly, a few thin myelin rings were detectable on
day 14, and, by day 28, numerous myelin basic protein (MBP)
positive myelin sheaths were observed throughout the lesion.
The results indicated that new matured oligodendrocytes
were mainly derived from OPCs and were able to produce
myelin sheaths in vivo. Further supporting evidence is made
available from transplantation experiments (see below). Cao
et al. studied whether treatment with exogenous OPCs could
alleviate demyelination and improve motor function [34].
Using OPCs expressing CNTF, grafted cells were found to
differentiate intomature oligodendrocytes.Notably, transcra-
nial magneticmotor-evoked potentials (tcMMEPs) andmag-
netic interenlargement reflex (MIER) showed a progressive
recovery in both the CNTF-expressing OPCs group and the
controlOPCs group; no restorationwas detected in nontrans-
plantation groups. In another spinal cord irradiation injury
model treated with mouse embryonic stem cells- (mESCs-)
derived OPCs, a reduction in lesion volume and an increase
in dorsal funiculus density were observed [39]. Forelimb
locomotion improved in the transplantation group when
compared with controls. These findings suggested that OPCs
were able to generate mature oligodendrocytes, which may
then become integrated and functional within the injury site.
It is important to note that OPCs may not be the only
endogenous progenitors of myelinating oligodendrocytes
after spinal cord trauma. Ependymal cells, located in the
central canal of spinal cord, possess neural stem/progenitor
cell properties and may respond extensively to insulting
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signals in spinal cord tissue. Such proliferative responses
seem to be exclusive to spinal cord trauma and do not occur
after chemical-induced demyelination [165]. Though, under
normal circumstances, the proliferative activity of ependymal
cells is only a tenth of that of OPCs, as soon as injury takes
place, ependymal cells would produce as much as double the
number of progenies compared to OPCs. Excitingly, a frac-
tion of these cells would finally differentiate into functioning
oligodendrocytes [166]. A recent study has demonstrated the
cholinergic enhancement of cell proliferation on ependy-
mal cells and, in turn, the upregulation in oligodendrocyte
markers in spinal cord tissue [167], thus shedding lights
on the possibility of endogenous oligodendrogenesis from
ependymal cells.
Since the promising findings in the origins and sources of
oligoregeneration and thewealthy understandings of endoge-
nous regulation of OPCs have been stated, is the remyeli-
nation complete? Such a speculation is cruelly diminished
by postmortem examinations providing disappointing results
with the presence of substantial amount of demyelinated
axons especially within the center of contused spinal cord
tissues [168]. And, given the difficulties with distinguish-
ing the boarder of injury epicenter and the chronic die
back of naked axons, pathological examinations focusing
on the injury site alone may potentially underestimate the
actual number of dysmyelinated or demyelinated axons after
spinal cord trauma. Spontaneous remyelination after CNS
injuries therefore remains a highly elusive phenomenon.
Recruitment of OPCs into injury site relies greatly on the
involvement of multiple stimulating factors, the levels of
which would diminish with age [169]. Another plausible
reason for insufficient remyelination after injury may be
the existence of myelin sheath debris containing inhibitory
molecules against OPCs differentiation such as NOGO66
via NOGO receptor complex [170]. Myelin sheaths that have
survived the initial insult may also inhibit the maturation of
OPCs probably by upregulating the expression of ID2 and ID4
[171]. Furthermore, glial scars formation would hinder not
only the recruitment and proliferation ofOPCs but also create
a hostile environment for OPCs differentiation and oligoden-
drocytes maturation. Paradoxically, OPCs themselves may
also partake in scar formation, suggesting a dual role of OPCs
after SCI (see below). Taken together, it is likely that myelin
sheaths repair and oligodendrocyte lineage regeneration are
hindered most significantly within the epicenter of injury,
whilst a more optimal site for regeneration may be found
along or even at a distance from the border of the injury [13].
Bone morphogenetic proteins (BMPs) belong to the
transforming growth factor-𝛽 (TGF-𝛽) super family.They act
on type I and type II BMPs receptors and are important neg-
ative regulators in oligodendrocyte lineage generation [172].
Earlier evidence demonstrated that the levels of BMPs would
alter after SCI [173]. Blockade of BMP4 by its extracellular
antagonist, Noggin, prohibited astrogenesis and promoted
the production of oligodendrocytes in OPCs culture [174].
Similarly, BMP4 was able to induce astrocyte generation
and suppress oligodendrocytes production via the Smad
pathways and other transcription factors [138, 173]. On the
other hand, intraventricular infusion of BMP4 has been
found to increase the number of OPCs during the demyeli-
nation phase. The number of OPCs significantly decreased
with an increase in astrocytosis during remyelination 1
week later. Antagonism of BMP4 by Noggin could enhance
remyelination and ablate the proastrogenesis effect of BMP4,
suggesting that BMPs may act in a phase-specific fashion
[174]. Understanding the role of BMP4 at different phases of
repair is therefore of translational significance.
As mentioned above, undamaged myelin sheaths can
inhibit remyelination via NOGO receptors. The latter inter-
act with leucine-rich repeat and Ig domain-containing 1
(LINGO-1), which is a major suppressor of OPCs differenti-
ation [175, 176]. Attenuating LINGO-1 significantly increased
the survival of oligodendrocytes and improved functional
recovery after spinal cord hemisection [177]. LINGO-1 may
also function as a negative regulator of neurotrophin BDNF
signaling through direct interaction with TrkB receptors
[178]. Another negative regulator is tumor necrosis factors-
alpha (TNF-𝛼). Both TNF-𝛼 and its receptor, TNF-R1, are
found in OPCs. Inhibition of TNF-𝛼 or TNF-R1 blockade
could significantly attenuate the inhibitory effects of reactive
astrocytes on OPCs differentiation at the epicenter of spinal
cord [179].
Generally speaking, there are two major strategies that
can potentially enhance remyelination: to increase the effects
of stimulating factors and to block the effects of inhibitory
factors.Themanipulation of a single factor alone is, however,
unlikely to the necessary effects, as exemplified by the failure
to enhance remyelination in transgenic mice overexpressing
PDGF-A despite an increase in OPCs density [180]. Some of
the factors, such as BMP4 and ZFP191, may have dual effects
that materialize in a phase-specific or region-specific fash-
ion. Therefore, therapeutic strategies targeted at endogenous
remyelination need to take into considerations the impacts
of different treatment time points, site of application, and,
most importantly, the combined effects of different factors.
Currently, the use of exogenous cell source and biomaterial
scaffolds have attracted considerable research effort.
4.3. Transplantation of Oligodendrocyte Precursor Cells. A
growing body of evidence has demonstrated that cellu-
lar transplantation may be of benefits. Various kinds of
transplantable cells, including olfactory ensheathing cells,
Schwann cells, and stem cell-derived OPCs, have been stud-
ied [181].The current understanding is that transplanted cells
would offer not somuch the replacement of damaged cells but
the neuroprotective and immunomodulatory effects. Herein,
we will highlight a few relevant studies.
4.3.1. OPCs. Franklin et al. transplanted lac-Z-transfected O-
2A progenitor cells (CG4, a cell line of OPCs) into irradiated
spinal cord and observed cell survival, proliferation, and
migration throughout the cord [35]. They further examined
the reactions of CG4 cells in an ethidium-bromide induced
demyelination lesion in both irradiated and nonirradiated
spinal cords. By day 15 after injury, remyelination was
evidentmicroscopically in preirradiated demyelinated lesion.
Interestingly, the injected cells appeared to survive better
in an injured environment than in the normal spinal cord,
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indicating that damaged axonsmay emit factors that promote
the survivals of OPCs. ExogenousOPCs transplanted directly
into the injured site seven days after injury were found to
have proliferated and differentiated into oligodendrocytes but
not astrocytes or neurons. Both motor function tests and
electrophysiological studies confirmed neurological recov-
ery [36]. The therapeutic effects of transgenic OPCs were
further demonstrated in SCI by Rosenbluth et al. [37] and
Bambakidis and Miller [38]. A summary of these pioneering
studies is provided in Table 1.
These preclinical studies have provided proof of concept
evidence that exogenous OPCs could enhance remyelina-
tion, but whether they can provide clinical benefit remains
unknown.The availability of autologous OPCs is limited and
heterologous transplantation requires the use of long-term
immunosuppression that may cause serious side effects [182].
A possible alternative is human embryonic stem cells (hESCs)
which are capable of differentiating into oligodendrocytes.
4.3.2. hESCs-Derived OPCs. hESCs are a potentially use-
ful source of OPCs for clinical application [39]. They are
also versatile, pluripotent “super cells” that are capable
of differentiating into serotonergic [183] and dopaminergic
neurons [184]. Nistor et al. described the method by which a
population of OPCs with high purity and specificity could be
generated from hESCs [185]. Using this technique, Keirstead
et al. reported doubling of remyelinated axons one week after
thoracic contusive SCI. Motor functions in the hESCs-OPCs-
treated group were significantly better than those in controls
[40].The same research group also demonstrated that hESCs-
OPCs transplantation was associated with better sparing of
grey and white matter, attenuated cavitation, and altered gene
expression (e.g., interleukin-10 (IL-10), hepatocyte growth
factor (HGF), and Fas) in cervical spinal cord contusion [41].
In terms of somatosensory evoked potentials (SSEPs) as a
surrogate of ascending pathway integrity [186], animals were
found to have significant improvement in both amplitudes
and latencies following transplantation [42].
These encouraging “proof-of-concept” studies have pro-
vided important evidence to support clinical trials. Recently,
a company (Asterias) has obtained an approval from the US
Food and Drug Administration to conduct a clinical phase
I and phase II/a trial of OPCs transplantation (AST-OPC1)
for SCI (NCT02302157, https://clinicaltrials.gov/).The trail is
expected to commence in early 2015 and will test escalating
dosages of transplanted cells and safety profile.
4.3.3. iPSCs-Derived OPCs. OPCs may also be generated
from induced pluripotent stem cells (iPSCs). iPSCs-derived
OPCs provide the solutions for simultaneously resolving two
major hurdles within transplantation therapy, that is, the
scarcity of cell source and the problem of immune-rejection.
iPSCs were derived from human dermal fibroblasts in 2007
[187]. Later, by genetically reprogramming several OPCs-
related transcription factors (OLIG2, SOX10, and NKX6.2)
in mouse fibroblasts cells, functional OPCs with normal
morphology and oligodendrogenesis abilities were generated
[188].
In 2011, Czepiel et al. succeeded in differentiating mouse
iPSCs into OPCs and myelinating oligodendrocytes in vitro
[44].Themajority of iPSCs-derivedOPCswere found to have
survived the procedure and could develop into functioning
oligodendrocytes that participated in remyelination [45].
All et al. similarly transplanted iPSCs-derived OPCs into
contused spinal cord and reported less cavitation together
with enhanced axonal remyelination two months after treat-
ment [46]. Perplexingly, both viable-OPCs group and Heat-
killed-control group (one of the controls) showed functional
improvement during the first seven days after transplan-
tation. However, further improvement in the viable-OPCs
group was not evident until the end of the first month.
Notwithstanding, these studies have shown that iPSCs-
derived OPCs are a potentially promising and clinically
accessible cell source.
Douvaras et al. have reported an interesting study
in which isolated skin fibroblasts from multiple sclerosis
patients were induced to form iPSCs and later OPCs. These
patient-iPSCs-derivedOPCswere able to initiatemyelination
well after being transplanted into shiverer mice with myelin
deficiency [47]. The limited migratory capacity of iPSC-
derived OPCs derived from iPSCs could also be overcome by
means of overexpressing polysialylating enzyme sialyltrans-
ferase X [48].
There are definite clinical risks associated with the use
of stem cell-derived OPCs. The tumorigenicity is a major
concern [189] even though no teratoma formation has so far
been reported in Keirstead’s serial studies [40, 41] or Geron’s
preclinical trial [190]. In another independent study, a total
of 650 million hESCs-derived OPCs were injected, again,
without any subsequent tumor-formation [43]. Another con-
cern is that clinical and experimental SCI involve different
pathological processes and that experimentalmodelsmay fail
to capture all critical elements found in clinical situations
[191]. Whether derived OPCs are able to generate new
oligodendrocytes and myelinate damaged axon is unknown.
In addition, there are ethical considerations with regard to
the use of human embryos that are beyond the scope of this
review.
4.3.4. Other Sources of Transplantable Cells. There are other
types of transplantable cells that are potentially useful for the
treatment of SCI including neural stem cells [192, 193], bone
marrow cells [194, 195], and Schwann cells [196, 197]. The
latter are the myelin-forming cells within the peripheral ner-
vous system. The major advantages of Schwann cells include
their accessibility and immune-compatibility. Their positive
roles in myelinating regenerated axons, reducing cyst forma-
tion, and improving neural functions have been extensively
studied. Another candidate for therapeutic transplantation
is olfactory ensheathing cells. Preclinical studies have shown
that these cells could promote remyelination [198, 199], and
autologous olfactory ensheathing cells are currently being
studied in clinical trials with some encouraging results [199–
202]. In a recent study using autologous olfactory lamina
propria transplantation, half of the patients with complete
SCI showed some improvement in either motor or sensory
functions upon long-term follow-up although the findings
BioMed Research International 9
Ta
bl
e
1:
Th
es
um
m
ar
y
of
O
PC
st
ra
ns
pl
an
ta
tio
n-
as
so
ci
at
ed
lit
er
at
ur
es
w
ith
in
th
er
ev
ie
w.
Re
fe
re
nc
es
C
el
ls
ut
ili
ze
d
In
vi
vo
m
od
els
Tr
an
sp
la
nt
at
io
n
str
at
eg
ie
s
Re
su
lts
Ti
m
ep
oi
nt
Q
ua
nt
ity
Lo
ca
tio
n
Ca
o
et
al
.[
34
]
CN
TF
-e
xp
re
ss
in
g
O
PC
sa
nd
re
gu
la
r
O
PC
s
C
on
tu
siv
es
pi
na
l
co
rd
in
ju
ry
(T
9)
8
da
ys
aft
er
in
ju
ry
4
×
10
5
1m
m
cr
an
ia
la
nd
ca
ud
al
to
th
el
es
io
n;
left
an
d
rig
ht
of
th
e
le
sio
n
Im
pl
an
te
d
O
PC
sd
ev
el
op
in
to
m
at
ur
eo
lig
od
en
dr
oc
yt
es
tc
M
M
EP
sa
nd
M
IE
R
co
nfi
rm
ap
ro
gr
es
siv
er
ec
ov
er
y
in
bo
th
CN
TF
-e
xp
re
ss
in
g
an
d
re
gu
la
rO
PC
s,
th
ou
gh
it
is
m
or
e
sig
ni
fic
an
ti
n
th
ef
or
m
er
gr
ou
p
Fr
an
kl
in
et
al
.
[3
5]
La
cZ
la
be
le
d
CG
4
ce
ll
lin
e
X-
irr
ad
ia
tio
n
pr
et
re
at
m
en
t
(T
12
to
L4
)
Et
hi
di
um
br
om
id
e-
in
du
ce
d
de
m
ye
lin
at
io
n
—
—
Le
sio
n
ce
nt
er
;
ad
ja
ce
nt
ar
ea
s;
re
m
ot
e
ar
ea
s
C
el
ls
su
rv
iv
e,
m
ig
ra
te
,a
nd
ar
er
em
ye
lin
at
ed
be
tte
ri
n
irr
ad
ia
te
d
co
rd
st
ha
n
no
ni
rr
ad
ia
te
d
co
rd
s
In
no
ni
rr
ad
ia
te
d
co
rd
s,
ad
ja
ce
nt
ly
tr
an
sp
la
nt
ed
ce
lls
co
nt
rib
ut
et
o
re
m
ye
lin
at
io
n,
w
he
re
as
re
m
ot
ely
tr
an
sp
la
nt
ed
ce
lls
do
no
t
Le
ee
ta
l.
[3
6]
O
-2
A
ce
lls
fro
m
P2
ra
tb
ra
in
C
on
tu
siv
es
pi
na
l
co
rd
in
ju
ry
(T
9)
7
da
ys
aft
er
in
ju
ry
5
×
10
5
Le
sio
n
ce
nt
er
Tr
an
sp
la
nt
ed
ce
lls
su
rv
iv
ea
nd
di
ffe
re
nt
ia
te
in
to
ol
ig
od
en
dr
oc
yt
es
bu
tn
ot
as
tro
cy
te
so
rn
eu
ro
ns
A
sig
ni
fic
an
ti
m
pr
ov
em
en
ti
n
hi
nd
lim
b
pe
rfo
rm
an
ce
Th
er
ea
re
no
di
ffe
re
nc
es
in
SS
EP
ss
tu
dy
,b
ut
th
el
at
en
cy
of
M
EP
si
ss
ho
rt
er
in
tr
an
sp
la
nt
at
io
n
gr
ou
p
Ro
se
nb
lu
th
et
al
.
[3
7]
Tr
an
sg
en
ic
m
ic
e
w
ith
La
cZ
ge
ne
un
de
rc
on
tro
lo
f
M
BP
pr
om
ot
er
C
on
tu
siv
es
pi
na
l
co
rd
in
ju
ry
(T
9
to
T1
0)
1d
ay
–1
6
da
ys
aft
er
in
ju
ry
1×
10
6
Le
sio
n
ce
nt
er
C
el
ls
m
ov
er
os
tro
ca
ud
al
ly
ov
er
co
ns
id
er
ab
le
di
sta
nc
es
an
d
m
or
er
ea
di
ly
to
de
m
ye
lin
at
ed
ar
ea
s
So
m
eo
ft
he
ce
lls
su
cc
ee
d
in
m
ye
lin
fo
rm
at
io
n
Ba
m
ba
ki
di
sa
nd
M
ill
er
[3
8]
O
PC
sf
ro
m
P0
ra
t
sp
in
al
co
rd
s
C
on
tu
siv
es
pi
na
l
co
rd
in
ju
ry
(T
9
to
T1
0)
5
da
ys
aft
er
in
ju
ry
1.5
×
10
5
Le
sio
n
ce
nt
er
Tr
an
sp
la
nt
at
io
n
of
O
PC
sw
ith
or
w
ith
ou
tS
H
H
im
pr
ov
es
ax
on
al
co
nd
uc
tio
n
(M
EP
s)
an
d
hi
nd
lim
bs
m
ot
or
fu
nc
tio
n
Th
eb
en
efi
ts
se
em
m
or
ep
ro
no
un
ce
d
w
ith
th
ea
dd
iti
on
of
SH
H
Su
n
et
al
.[
39
]
m
ES
Cs
-d
er
iv
ed
O
PC
s
Ir
ra
di
at
io
n
sp
in
al
co
rd
in
ju
ry
(C
4-
C5
)
4
m
on
th
sa
fte
r
irr
ad
ia
tio
n
2
×
10
5
4m
m
cr
an
ia
la
nd
ca
ud
al
to
th
e
irr
ad
ia
te
d
sit
e
Tr
an
sp
la
nt
ed
m
ES
Cs
-d
er
iv
ed
O
PC
ss
ur
vi
ve
,m
ig
ra
te
,a
nd
di
ffe
re
nt
ia
te
in
to
ol
ig
od
en
dr
oc
yt
es
w
ith
in
th
ei
rr
ad
ia
te
d
le
sio
n
H
ist
ol
og
ic
al
ex
am
in
at
io
n
sh
ow
sa
na
rr
ow
ed
ca
vi
ta
tio
n
an
d
a
do
rs
al
fu
ni
cu
lu
sw
ith
in
cr
ea
se
d
de
ns
iti
es
Lo
co
m
ot
io
n
of
fo
re
lim
bs
is
im
pr
ov
ed
in
tr
an
sp
la
nt
at
io
n
gr
ou
p
Ke
irs
te
ad
et
al
.
[4
0]
hE
SC
s-
de
riv
ed
O
PC
s
C
on
tu
sio
n
sp
in
al
co
rd
in
ju
ry
(T
10
)
7
da
ys
an
d
10
m
on
th
sa
fte
r
in
ju
ry
1.5
×
10
6
4m
m
cr
an
ia
la
nd
ca
ud
al
to
th
el
es
io
n
ce
nt
er
7-
da
y
gr
ou
p:
O
PC
ss
ur
vi
ve
,d
iff
er
en
tia
te
in
to
ol
ig
od
en
dr
oc
yt
es
,a
nd
re
m
ye
lin
at
ea
xo
ns
;B
BB
sc
or
es
ar
e
sig
ni
fic
an
tly
hi
gh
er
in
O
PC
s-
tre
at
ed
ra
ts
10
-d
ay
gr
ou
p:
O
PC
ss
ur
vi
ve
an
d
di
ffe
re
nt
ia
te
in
to
ol
ig
od
en
dr
oc
yt
es
bu
td
o
no
tp
ar
tic
ip
at
ei
n
re
m
ye
lin
at
io
n;
th
er
ei
sn
o
im
pr
ov
em
en
ti
n
BB
B
sc
or
es
10 BioMed Research International
Ta
bl
e
1:
C
on
tin
ue
d.
Re
fe
re
nc
es
C
el
ls
ut
ili
ze
d
In
vi
vo
m
od
els
Tr
an
sp
la
nt
at
io
n
str
at
eg
ie
s
Re
su
lts
Ti
m
ep
oi
nt
Q
ua
nt
ity
Lo
ca
tio
n
Sh
ar
p
et
al
.[
41
]
hE
SC
s-
de
riv
ed
O
PC
s
C
on
tu
sio
n
sp
in
al
co
rd
in
ju
ry
(C
5)
7
da
ys
aft
er
in
ju
ry
1.5
×
10
6
Cr
an
ia
la
nd
ca
ud
al
to
th
el
es
io
n
ce
nt
er
(in
te
rv
al
is
un
kn
ow
n)
Tr
an
sp
la
nt
ed
ce
lls
su
rv
iv
e,
re
di
st
rib
ut
e,
an
d
di
ffe
re
nt
ia
te
in
th
ei
nj
ur
y
sit
es
;O
PC
s-
re
m
ye
lin
at
io
n
effi
ci
en
cy
is
m
uc
h
hi
gh
er
BB
B
sc
or
es
,f
or
el
im
b
str
id
el
en
gt
h,
an
d
ra
ng
eo
fm
ot
io
n
ar
e
im
pr
ov
ed
sig
ni
fic
an
tly
O
PC
st
ra
ns
pl
an
ta
tio
n
im
pr
ov
es
ax
on
sp
ar
in
g
an
d
at
te
nu
at
es
ca
vi
ta
tio
n;
it
al
so
al
te
rs
th
ei
nj
ur
y-
in
du
ce
d
ge
ne
ex
pr
es
sio
n
(I
L1
0,
Fa
s,
H
G
F,
et
c.)
A
ll
et
al
.[
42
]
hE
SC
s-
de
riv
ed
O
PC
s
C
on
tu
sio
n
sp
in
al
co
rd
in
ju
ry
(T
8)
2
ho
ur
sa
fte
r
in
ju
ry
1×
10
6
Le
sio
n
sit
e;
4m
m
cr
an
ia
la
nd
1m
m
le
ft;
4m
m
ca
ud
al
an
d
1m
m
rig
ht
Tr
an
sp
la
nt
ed
ce
lls
su
rv
iv
ea
nd
di
ffe
re
nt
ia
te
in
to
m
ye
lin
at
in
g
ol
ig
od
en
dr
oc
yt
es
w
hi
le
no
as
tro
ge
ne
sis
is
ob
se
rv
ed
O
PC
st
ra
ns
pl
an
ta
tio
n
sh
ow
si
m
pr
ov
em
en
ti
n
SS
EP
s
am
pl
itu
de
sa
nd
lat
en
ci
es
Ca
vi
ta
tio
n
in
tre
at
ed
gr
ou
p
is
at
te
nu
at
ed
,a
nd
LF
B
st
ai
ni
ng
is
m
uc
h
hi
gh
er
Ke
rr
et
al
.[
43
]
hE
SC
s-
de
riv
ed
O
PC
s
C
on
tu
sio
n
sp
in
al
co
rd
in
ju
ry
(T
8)
3
an
d
24
ho
ur
s
aft
er
in
ju
ry
1.5
×
10
5
5
×
10
5 ,
re
sp
ec
tiv
ely
T7
an
d
T9
A
nd
T8
Tr
an
sp
la
nt
ed
ce
lls
su
rv
iv
ea
nd
m
ig
ra
te
w
el
lw
ith
ou
tt
um
or
or
cy
st
fo
rm
at
io
n
Be
ha
vi
or
al
an
d
ele
ct
ro
ph
ys
io
lo
gi
ca
le
xa
m
in
at
io
n
im
pr
ov
es
in
th
eO
PC
s-
tre
at
ed
gr
ou
p
Cz
ep
ie
le
ta
l.
[4
4]
iP
SC
s-
de
riv
ed
O
PC
s
In
vi
tro
:c
oc
ul
tu
re
of
iP
SC
s-
de
riv
ed
O
PC
s
an
d
D
RG
s
In
vi
vo
:
cu
pr
iz
on
e-
in
du
ce
d
de
m
ye
lin
at
io
n
m
ou
se
m
od
el
—
1×
10
5
C
or
pu
sc
al
lo
su
m
In
vi
tro
:e
xt
en
siv
em
ye
lin
fo
rm
at
io
n
ar
ou
nd
na
ke
d
ax
on
s
In
vi
vo
:8
0%
ce
lls
do
no
ts
ur
vi
ve
th
ei
nj
ec
tio
n,
w
hi
le
su
rv
iv
ed
on
es
de
ve
lo
p
in
to
m
at
ur
eo
lig
od
en
dr
oc
yt
es
Te
ra
to
m
ai
ss
ee
n
in
ra
ts
tre
at
ed
w
ith
ce
lls
co
nt
ai
ni
ng
un
di
ffe
re
nt
ia
te
d
iP
SC
s
Po
uy
ae
ta
l.
[4
5]
iP
SC
s-
de
riv
ed
O
PC
s
O
pt
ic
ch
ia
sm
de
m
ye
lin
at
io
n
by
ly
so
le
ci
th
in
1w
ee
k
aft
er
ly
so
le
ci
th
in
ad
m
in
ist
ra
tio
n
2
×
10
5
Ch
ia
sm
A
re
du
ct
io
n
in
lat
en
ci
es
of
V
EP
si
n
tr
an
sp
la
nt
at
io
n
gr
ou
p
is
se
en
Tr
an
sp
la
nt
ed
O
PC
si
nt
eg
ra
te
an
d
di
ffe
re
nt
ia
te
in
to
ol
ig
od
en
dr
oc
yt
es
A
ll
et
al
.[
46
]
iP
SC
s-
de
riv
ed
O
PC
s
C
on
tu
sio
n
sp
in
al
co
rd
in
ju
ry
(T
8)
24
ho
ur
sa
fte
r
in
ju
ry
5
×
10
5
Le
sio
n
sit
e
O
PC
st
ra
ns
pl
an
ta
tio
n
re
du
ce
sc
av
ita
tio
n,
sc
ar
sf
or
m
at
io
n,
an
d
m
ic
ro
gl
ia
lp
ro
lif
er
at
io
n
Tr
an
sp
la
nt
ed
O
PC
sd
iff
er
en
tia
te
an
d
ar
er
em
ye
lin
at
ed
in
th
e
le
sio
n
BB
B
sc
or
es
im
pr
ov
em
en
ti
so
nl
y
sig
ni
fic
an
tly
se
en
aft
er
th
e
fir
st
m
on
th
BioMed Research International 11
Ta
bl
e
1:
C
on
tin
ue
d.
Re
fe
re
nc
es
C
el
ls
ut
ili
ze
d
In
vi
vo
m
od
els
Tr
an
sp
la
nt
at
io
n
str
at
eg
ie
s
Re
su
lts
Ti
m
ep
oi
nt
Q
ua
nt
ity
Lo
ca
tio
n
D
ou
va
ra
se
ta
l.
[4
7]
O
PC
si
nd
uc
ed
fro
m
iP
SC
s
de
riv
ed
fro
m
M
S
pa
tie
nt
s
(h
iP
SC
s-
de
riv
ed
O
PC
s)
;
hE
SC
s-
de
riv
ed
O
PC
s
Sh
iv
er
er
/r
ag
2
m
ic
e
—
1×
10
5
(5
×
10
4
ea
ch
sid
e)
Bi
la
te
ra
lly
at
ad
ep
th
of
1.1
m
m
in
to
th
e
co
rp
us
ca
llo
su
m
O
PC
sc
an
be
effi
ci
en
tly
ge
ne
ra
te
d
fro
m
hi
PS
Cs
Ve
ry
fe
w
hi
PS
Cs
-O
PC
sd
iff
er
en
tia
te
in
to
as
tro
cy
te
s,
an
d
no
ne
ur
on
sa
re
fo
un
d
Tr
an
sp
la
nt
ed
hi
PS
Cs
-O
PC
sa
re
m
ye
lin
at
ed
in
th
eb
ra
in
Cz
ep
ei
le
ta
l.
[4
8]
iP
SC
s-
de
riv
ed
O
PC
sw
ith
ov
er
ex
pr
es
sio
n
of
ST
X
In
vi
tro
:c
oc
ul
tu
re
of
iP
SC
s-
de
riv
ed
O
PC
s
an
d
D
RG
s
In
vi
vo
:
cu
pr
iz
on
e-
in
du
ce
d
de
m
ye
lin
at
io
n
m
ou
se
m
od
el
—
1×
10
5
C
or
pu
sc
al
lo
su
m
ST
X-
tre
at
ed
O
PC
ss
ho
w
as
ig
ni
fic
an
tly
in
cr
ea
se
d
m
ig
ra
to
ry
ab
ili
ty
in
vi
tro
an
d
in
vi
vo
Su
rv
iv
al
an
d
m
at
ur
at
io
n
pa
tte
rn
of
ST
X-
tre
at
ed
an
d
co
nt
ro
l
O
PC
sa
re
sim
ila
r
BB
B
sc
or
es
:B
as
so
,B
ea
tti
e,
an
d
Br
es
na
ha
n
sc
or
es
;C
N
TF
:c
ili
ar
y
ne
ur
ot
ro
ph
ic
fa
ct
or
;D
RG
s:
do
rs
al
ro
ot
ga
ng
lio
n
ne
ur
on
s;
H
G
F:
he
pa
to
cy
te
gr
ow
th
fa
ct
or
;I
L-
10
:i
nt
er
le
uk
in
-1
0;
LF
B:
Lu
xo
lf
as
tb
lu
e;
M
BP
:m
ye
lin
ba
sic
pr
ot
ei
n;
M
EP
s:
m
ot
or
ev
ok
ed
po
te
nt
ia
ls;
SH
H
:s
on
ic
he
dg
eh
og
;S
TX
:s
ia
ly
ltr
an
sfe
ra
se
X;
SS
EP
s:
so
m
at
os
en
so
ry
ev
ok
ep
ot
en
tia
ls;
tc
M
M
EP
s:
tr
an
sc
ra
ni
al
m
ag
ne
tic
m
ot
or
-e
vo
ke
d
po
te
nt
ia
l;V
EP
s:
vi
su
al
ev
ok
ed
po
te
nt
ia
ls.
12 BioMed Research International
are not conclusive [203]. The authors tried to link several
reasons to their results, one of which was the relatively
small size of input graft when compared with the lesion
size. Indecipherable enlargement of syringomyelia might also
contribute to the mere recovery in this study. From our point
of view, another plausible reason may be the long time span
since spinal cord trauma (not less than 6 months), as it is
indicated that benefits may not be witnessed when treatment
is carried out after a several months-long period of time [40].
4.4. Inhibition by Oligodendrocyte Precursor Cells. Astroglio-
sis and glial scar formation are ubiquitous findings in SCI
[204–206]. Although they serve important functions during
the acute and subacute phases of injury, chronic scarring
would limit axonal regeneration [207, 208]. The observation
of extensive OPCs proliferation along injury boundaries
also raises the question of whether these cells may in fact
contribute to scarring. There are two main areas within a
glial scar—the fibroblastic core and the glial surrounding
zone [209]. NG2-positive cells were known to populate lesion
cavities 2 days after injury, and, by day 10, these cells formed
small plaques that corresponded to the glial surrounding
zone. Similarly, oligodendrocytes precursors have also been
identified within the fibroblastic core [210]. Hence, there
is evidence to suggest that OPCs may also partake in the
formation of glial scar that prohibits axonal regeneration.
Apart from being a physical barrier against regeneration,
a glial scar may also act as a source of inhibitory molecules,
including chondroitin sulfate proteoglycans (CSPGs),
semaphorin 3, and eph/ephrin tyrosine kinases [211]. CSPGs
consist of several subtypes (e.g., aggrecan, versican, NG2,
neurocan, brevican, and phosphacan) and are closely linked
with OPCs [212, 213]. Amongst these, NG2 is of particular
interests. Chen et al. found that growing neurites would
avoid OPCs-covered areas in vitro. But when incubated
with anti-NG2 antisera, these OPCs-coated membranes
would attract neurite ingrowth, suggesting that NG2 may be
responsible for the growth-inhibiting effect of CSPGs [214].
The underlying mechanism is incompletely understood
but may involve the activations of the N-terminal globular
domain (domain 1) and the juxtamembrane domain (domain
3) of NG2 [215]. Results from subsequent in vivo studies
were less clear-cut, however. de Castro et al. compared
between wild-type and NG2 knockout mice and found
no difference in the morphology of the transection scar.
Surprisingly, calcitonin gene-related protein-positive fibers
were found to grow into the scars in wild-type animals just
as extensively as in NG2-null ones [216]. On the other hand,
blockage of NG2 has been shown to facilitate the growth
of ascending sensory axons across the caudal boundary of
a lesion [217]. Similar growth-promoting effects could also
be achieved by using chondroitinase ABC [218] and NG2
neutralizing antibodies [219]. There is as yet no satisfactory
explanation for these controversial findings but differences
in regenerating capabilities between subtypes of neurons
may be responsible.
Recent studies also suggested that CSPGs might affect
the formation of cellular processes by OPCs and oligoden-
drocytes. In an in vitro study, the presence of CSPGSs was
found to reduce the length and number of processes in
predifferentiated OPCs [220]. Furthermore, CSPGs could
affect myelination, resulting in fewer membrane sheets that
were smaller and atrophic [221]. Both Rho-Rock and protein
kinase C signaling pathways [221], as well as the protein
tyrosine phosphatase sigma (PTP𝜎) pathway [222], were
thought to play important roles. Conversely, the reduction of
CSPGs by xyloside was found to result in a robust increase
in OPCs number as well as CC1+ mature oligodendrocytes
in a mouse model of lysolecithin-injected spinal cord injury
[223]. To further complicate the picture, different classes of
CSPGs may exert different effects on OPCs [160]. Therefore,
further researches are clearly needed.
5. Conclusions
Demyelination and oligodendrocyte loss following SCI cause
significant interruption of neural functions. Current evi-
dence supports the notion that efficient oligodendrocyte
replacement and sufficient remyelination would ameliorate
pathological cascades and improve neural functions. OPCs
are the natural source ofmyelinating oligodendrocytes within
the CNS following SCI. The enhancement of endogenous
regeneration by innate OPCs and the transplantation of
myelinating cells represent the two most promising thera-
peutic strategies. The elusive biological properties of OPCs
and the complexity of the associated regulatory network are
incompletely understood and continue to be a critical area
of future investigations. A simplistic approach of targeting
a single factor is unlikely to provide significant clinical
benefit. The latter would necessitate a far more thorough
understanding and exploitation of the complex regulatory
network.
In the context of transplantation, OPCs derived from dif-
ferent sources may respond differently to individual growth
factors and within different regions around the injury site
[97, 101]. More intriguing is the possible role of OPCs in
promoting glial scar formation that may itself inhibit axonal
regeneration, and it is conceivable that future discoveriesmay
argue against the utilization of OPCs transplantation in the
treatment of SCI and other demyelinating conditions. The
situation is further complicated by the fact that CSPGs may
in turn prohibit OPCs. Existing evidence suggests that adult
OPCs contribute to CSPGs accumulation at the lesion site
after injury and that premature oligodendrocytes probably do
not [213].This renders premature oligodendrocytes an attrac-
tive source of transplantable cells that are capable of generat-
ingmature oligodendrocytes without emittingCSPGs. Again,
given the extremely complicated neuron-glial, glial-glial, and
extracellular matrix-glial cross talks, it is unlikely that single-
agent treatment would be effective; instead, combinatorial
strategies targeted at oligodendrocytes lineage protection,
blockage of extracellular inhibitory molecules, and myelina-
tion promotion are probably necessary.
Conflict of Interests
The authors declare no conflict of interests regarding in
publication of this paper.
BioMed Research International 13
References
[1] R. A. Watson and T. M. Yeung, “What is the potential of
oligodendrocyte progenitor cells to successfully treat human
spinal cord injury?” BMC Neurology, vol. 11, article 113, 2011.
[2] B. Lenehan, J. Street, B. K. Kwon et al., “The epidemiology
of traumatic spinal cord injury in British Columbia, Canada,”
Spine, vol. 37, no. 4, pp. 321–329, 2012.
[3] G.-Z. Ning, Q. Wu, Y.-L. Li, and S.-Q. Feng, “Epidemiology
of traumatic spinal cord injury in Asia: a systematic review,”
Journal of Spinal CordMedicine, vol. 35, no. 4, pp. 229–239, 2012.
[4] M. M. P. Solda´n and I. Pirko, “Biogenesis and significance of
central nervous system myelin,” Seminars in Neurology, vol. 32,
no. 1, pp. 9–14, 2012.
[5] V. E.Miron, T. Kuhlmann, and J. P. Antel, “Cells of the oligoden-
droglial lineage, myelination, and remyelination,” Biochimica et
Biophysica Acta—Molecular Basis of Disease, vol. 1812, no. 2, pp.
184–193, 2011.
[6] S. D. Grossman, L. J. Rosenberg, and J. R. Wrathall, “Temporal-
spatial pattern of acute neuronal and glial loss after spinal cord
contusion,” Experimental Neurology, vol. 168, no. 2, pp. 273–282,
2001.
[7] J. M. Lytle and J. R. Wrathall, “Glial cell loss, proliferation and
replacement in the contused murine spinal cord,” European
Journal of Neuroscience, vol. 25, no. 6, pp. 1711–1724, 2007.
[8] M. O. Totoiu and H. S. Keirstead, “Spinal cord injury is
accompanied by chronic progressive demyelination,” Journal of
Comparative Neurology, vol. 486, no. 4, pp. 373–383, 2005.
[9] G. L. Li, M. Farooque, A. Holtz, and Y. Olsson, “Apoptosis
of oligodendrocytes occurs for long distances away from the
primary injury after compression trauma to rat spinal cord,”
Acta Neuropathologica, vol. 98, no. 5, pp. 473–480, 1999.
[10] A. Delshad and T. Al-Tiraihi, “Ultrastructure of apoptotic
oligodendrocytes in the spinal cord of adult rat with long-
standing axotomised sciatic nerve,” Folia Neuropathologica, vol.
39, no. 3, pp. 125–128, 2001.
[11] T. Takagi, M. Takayasu, M. Mizuno, M. Yoshimoto, and J.
Yoshida, “Caspase activation in neuronal and glial apoptosis
following spinal cord injury in mice,” Neurologia Medico-
Chirurgica, vol. 43, no. 1, pp. 20–29, 2003.
[12] A. Almad, F. R. Sahinkaya, and D. M. McTigue, “Oligodendro-
cyte fate after spinal cord injury,” Neurotherapeutics, vol. 8, no.
2, pp. 262–273, 2011.
[13] J. R. Plemel, M. B. Keough, G. J. Duncan et al., “Remyelination
after spinal cord injury: is it a target for repair?” Progress in
Neurobiology, vol. 117, pp. 54–72, 2014.
[14] H. Kanno, H. Ozawa, A. Sekiguchi, S. Yamaya, and E. Itoi,
“Induction of autophagy and autophagic cell death in damaged
neural tissue after acute spinal cord injury in mice,” Spine, vol.
36, no. 22, pp. E1427–E1434, 2011.
[15] H. Kanno, H. Ozawa, A. Sekiguchi, and E. Itoi, “Spinal
cord injury induces upregulation of Beclin 1 and promotes
autophagic cell death,” Neurobiology of Disease, vol. 33, no. 2,
pp. 143–148, 2009.
[16] C. M. Smith, J. A. Mayer, and I. D. Duncan, “Autophagy
promotes oligodendrocyte survival and function following
dysmyelination in a long-lived myelin mutant,” The Journal of
Neuroscience, vol. 33, no. 18, pp. 8088–8100, 2013.
[17] I. R. Griffiths andM. C.McCulloch, “Nerve fibres in spinal cord
impact injuries. Part 1. Changes in the myelin sheath during the
initial 5 weeks,” Journal of the Neurological Sciences, vol. 58, no.
3, pp. 335–349, 1983.
[18] K. M. Young, K. Psachoulia, R. B. Tripathi et al., “Oligodendro-
cyte dynamics in the healthy adult CNS: evidence for myelin
remodeling,” Neuron, vol. 77, no. 5, pp. 873–885, 2013.
[19] S. Y. C. Chong, S. S. Rosenberg, S. P. J. Fancy et al., “Neurite
outgrowth inhibitor Nogo-A establishes spatial segregation
and extent of oligodendrocyte myelination,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 109, no. 4, pp. 1299–1304, 2012.
[20] I. Griffiths, M. Klugmann, T. Anderson et al., “Axonal swellings
and degeneration in mice lacking the major proteolipid of
myelin,” Science, vol. 280, no. 5369, pp. 1610–1613, 1998.
[21] C. Lappe-Siefke, S. Goebbels, M. Gravel et al., “Disruption of
Cnp1 uncouples oligodendroglial functions in axonal support
and myelination,” Nature Genetics, vol. 33, no. 3, pp. 366–374,
2003.
[22] T. Nguyen, N. R. Mehta, K. Conant et al., “Axonal protective
effects of the myelin-associated glycoprotein,” The Journal of
Neuroscience, vol. 29, no. 3, pp. 630–637, 2009.
[23] M. Tanaka, T. Izawa, J. Yamate et al., “The VF rat with abnormal
myelinogenesis has a mutation in Dopey1,” Glia, vol. 62, no. 9,
pp. 1530–1542, 2014.
[24] K.-A. Nave, “Myelination and the trophic support of long
axons,” Nature Reviews Neuroscience, vol. 11, no. 4, pp. 275–283,
2010.
[25] S. B. Tekko¨k, A.M. Brown, R.Westenbroek, L. Pellerin, andB. R.
Ransom, “Transfer of glycogen-derived lactate from astrocytes
to axons via specific monocarboxylate transporters supports
mouse optic nerve activity,” Journal of Neuroscience Research,
vol. 81, no. 5, pp. 644–652, 2005.
[26] U. Fu¨nfschilling, L. M. Supplie, D. Mahad et al., “Gly-
colytic oligodendrocytesmaintainmyelin and long-term axonal
integrity,” Nature, vol. 485, no. 7399, pp. 517–521, 2012.
[27] S. Baltan, “Can lactate serve as an energy substrate for axons in
good times and in bad, in sickness and in health?” Metabolic
Brain Disease, vol. 30, no. 1, pp. 25–30, 2015.
[28] Y. Lee, B. M. Morrison, Y. Li et al., “Oligodendroglia metabol-
ically support axons and contribute to neurodegeneration,”
Nature, vol. 487, no. 7408, pp. 443–448, 2012.
[29] E. Adriano, L. Perasso, I. Panfoli et al., “A novel hypothesis about
mechanisms affecting conduction velocity of centralmyelinated
fibers,” Neurochemical Research, vol. 36, no. 10, pp. 1732–1739,
2011.
[30] S. Ravera, M. Bartolucci, E. Adriano et al., “Support of nerve
conduction by respiring myelin sheath: role of connexons,”
Molecular Neurobiology, 2015.
[31] A.Morelli, S. Ravera, and I. Panfoli, “Hypothesis of an energetic
function for myelin,” Cell Biochemistry and Biophysics, vol. 61,
no. 1, pp. 179–187, 2011.
[32] J. M. Edgar, M. McLaughlin, H. B. Werner et al., “Early
ultrastructural defects of axons and axon-glia junctions in mice
lacking expression of Cnp1,”GLIA, vol. 57, no. 16, pp. 1815–1824,
2009.
[33] C. M. Kassmann, C. Lappe-Siefke, M. Baes et al., “Axonal
loss and neuroinflammation caused by peroxisome-deficient
14 BioMed Research International
oligodendrocytes,” Nature Genetics, vol. 39, no. 8, pp. 969–976,
2007.
[34] Q. Cao, Q. He, Y. Wang et al., “Transplantation of ciliary
neurotrophic factor-expressing adult oligodendrocyte precur-
sor cells promotes remyelination and functional recovery after
spinal cord injury,” Journal of Neuroscience, vol. 30, no. 8, pp.
2989–3001, 2010.
[35] R. J. M. Franklin, S. A. Bayley, and W. F. Blakemore, “Trans-
planted CG4 cells (an oligodendrocyte progenitor cell line) sur-
vive, migrate, and contribute to repair of areas of demyelination
in X-irradiated and damaged spinal cord but not in normal
spinal cord,” Experimental Neurology, vol. 137, no. 2, pp. 263–
276, 1996.
[36] K. H. Lee, D. H. Yoon, Y. G. Park, and B. H. Lee, “Effects of glial
transplantation on functional recovery following acute spinal
cord injury,” Journal of Neurotrauma, vol. 22, no. 5, pp. 575–589,
2005.
[37] J. Rosenbluth, R. Schiff, W.-L. Liang, G. Menna, and W.
Young, “Xenotransplantation of transgenic oligodendrocyte-
lineage cells into spinal cord-injured adult rats,” Experimental
Neurology, vol. 147, no. 1, pp. 172–182, 1997.
[38] N. C. Bambakidis and R. H. Miller, “Transplantation of oligo-
dendrocyte precursors and sonic hedgehog results in improved
function and white matter sparing in the spinal cords of adult
rats after contusion,” Spine Journal, vol. 4, no. 1, pp. 16–26, 2004.
[39] Y. Sun, C.-C. Xu, J. Li et al., “Transplantation of oligodendrocyte
precursor cells improves locomotion deficits in rats with spinal
cord irradiation injury,” PLoS ONE, vol. 8, no. 2, Article ID
e57534, 2013.
[40] H. S. Keirstead, G. Nistor, G. Bernal et al., “Human embryonic
stem cell-derived oligodendrocyte progenitor cell transplants
remyelinate and restore locomotion after spinal cord injury,”
Journal of Neuroscience, vol. 25, no. 19, pp. 4694–4705, 2005.
[41] J. Sharp, J. Frame, M. Siegenthaler, G. Nistor, and H. S.
Keirstead, “Human embryonic stem cell-derived oligodendro-
cyte progenitor cell transplants improve recovery after cervical
spinal cord injury,” Stem Cells, vol. 28, no. 1, pp. 152–163, 2010.
[42] A. H. All, F. A. Bazley, S. Gupta et al., “Human embryonic
stem cell-derived oligodendrocyte progenitors aid in functional
recovery of sensory pathways following contusive spinal cord
injury,” PLoS ONE, vol. 7, no. 10, Article ID e47645, 2012.
[43] C. L. Kerr, B. S. Letzen, C.M.Hill et al., “Efficient differentiation
of human embryonic stem cells into oligodendrocyte progen-
itors for application in a rat contusion model of spinal cord
injury,” International Journal of Neuroscience, vol. 120, no. 4, pp.
305–313, 2010.
[44] M. Czepiel, V. Balasubramaniyan, W. Schaafsma et al., “Dif-
ferentiation of induced pluripotent stem cells into functional
oligodendrocytes,” Glia, vol. 59, no. 6, pp. 882–892, 2011.
[45] A. Pouya, L. Satarian, S. Kiani, M. Javan, and H. Baharvand,
“Human induced pluripotent stem cells differentiation into
oligodendrocyte progenitors and transplantation in a rat model
of optic chiasm demyelination,” PLoS ONE, vol. 6, no. 11, Article
ID e27925, 2011.
[46] A. H. All, P. Gharibani, S. Gupta et al., “Early intervention for
spinal cord injury with human induced pluripotent stem cells
oligodendrocyte progenitors,” PLoS ONE, vol. 10, no. 1, Article
ID e0116933, 2015.
[47] P. Douvaras, J. Wang, M. Zimmer et al., “Efficient generation
of myelinating oligodendrocytes from primary progressive
multiple sclerosis patients by induced pluripotent stem cells,”
Stem Cell Reports, vol. 3, no. 2, pp. 250–259, 2014.
[48] M. Czepiel, L. Leicher, K. Becker, E. Boddeke, and S. Copray,
“Overexpression of polysialylated neural cell adhesionmolecule
improves the migration capacity of induced pluripotent stem
cell-derived oligodendrocyte precursors,” Stem Cells Transla-
tional Medicine, vol. 3, no. 9, pp. 1100–1109, 2014.
[49] J. E. Vaughn and A. Peters, “A third neuroglial cell type. An
electron microscopic study,” Journal of Comparative Neurology,
vol. 133, no. 2, pp. 269–288, 1968.
[50] R. P. Skoff and J. E. Vaughn, “An autoradiographic study of
cellular proliferation in degenerating rat optic nerve,” Journal
of Comparative Neurology, vol. 141, no. 2, pp. 133–155, 1971.
[51] J. E. Vaughn, P. L. Hinds, and R. P. Skoff, “Electron microscopic
studies of Wallerian degeneration in rat optic nerves. I. The
multipotential glia,” Journal of Comparative Neurology, vol. 140,
no. 2, pp. 175–206, 1970.
[52] M. C. Raff, R. H. Miller, and M. Noble, “A glial progenitor cell
that develops in vitro into an astrocyte or an oligodendrocyte
depending on culture medium,” Nature, vol. 303, no. 5916, pp.
390–396, 1983.
[53] C. Ffrench-Constant and M. C. Raff, “Proliferating bipotential
glial progenitor cells in adult rat optic nerve,” Nature, vol. 319,
no. 6053, pp. 499–502, 1986.
[54] J. Shi, A. Marinovich, and B. A. Barres, “Purification and
characterization of adult oligodendrocyte precursor cells from
the rat optic nerve,”The Journal of Neuroscience, vol. 18, no. 12,
pp. 4627–4636, 1998.
[55] J. M. Levine, R. Reynolds, and J. W. Fawcett, “The oligo-
dendrocyte precursor cell in health and disease,” Trends in
Neurosciences, vol. 24, no. 1, pp. 39–47, 2001.
[56] M. R. L. Dawson, A. Polito, J. M. Levine, and R. Reynolds,
“NG2-expressing glial progenitor cells: an abundant and
widespread population of cycling cells in the adult rat CNS,”
Molecular and Cellular Neuroscience, vol. 24, no. 2, pp. 476–488,
2003.
[57] Y. Chen, V. Balasubramaniyan, J. Peng et al., “Isolation and
culture of rat and mouse oligodendrocyte precursor cells,”
Nature Protocols, vol. 2, no. 5, pp. 1044–1051, 2007.
[58] T. Kondo and M. Raff, “Oligodendrocyte precursor cells repro-
grammed to become multipotential CNS stem cells,” Science,
vol. 289, no. 5485, pp. 1754–1757, 2000.
[59] G. Vogel, “Developmental biology: brain cells turning over a
new leaf,” Science, vol. 289, no. 5485, Article ID 1666a, 2000.
[60] S. Belachew, R. Chittajallu, A. A. Aguirre et al., “Postnatal
NG2 proteoglycan-expressing progenitor cells are intrinsically
multipotent and generate functional neurons,” Journal of Cell
Biology, vol. 161, no. 1, pp. 169–186, 2003.
[61] M. C. Nunes, N. S. Roy, H. M. Keyoung et al., “Identification
and isolation of multipotential neural progenitor cells from
the subcortical white matter of the adult human brain,” Nature
Medicine, vol. 9, no. 4, pp. 439–447, 2003.
[62] F. Guo, Y. Maeda, J. Ma et al., “Pyramidal neurons are generated
from oligodendroglial progenitor cells in adult piriform cortex,”
Journal of Neuroscience, vol. 30, no. 36, pp. 12036–12049, 2010.
BioMed Research International 15
[63] L. E. Rivers, K. M. Young, M. Rizzi et al., “PDGFRA/NG2 glia
generate myelinating oligodendrocytes and piriform projection
neurons in adult mice,” Nature Neuroscience, vol. 11, no. 12, pp.
1392–1401, 2008.
[64] Y. Tamura, Y. Kataoka, Y. Cui, Y. Takamori, Y. Watanabe, and
H. Yamada, “Multi-directional differentiation of doublecortin-
and NG2-immunopositive progenitor cells in the adult rat
neocortex in vivo,”European Journal of Neuroscience, vol. 25, no.
12, pp. 3489–3498, 2007.
[65] F. Guo, J. Ma, E. McCauley, P. Bannerman, and D. Pleasure,
“Early postnatal proteolipid promoter-expressing progenitors
produce multilineage cells in vivo,”The Journal of Neuroscience,
vol. 29, no. 22, pp. 7256–7270, 2009.
[66] D. E. Bergles, J. D. B. Roberts, P. Somogyl, and C. E. Jahr,
“Glutamatergic synapses on oligodendrocyte precursor cells in
the hippocampus,” Nature, vol. 405, no. 6783, pp. 187–191, 2000.
[67] J. L. Ziskin, A. Nishiyama, M. Rubio, M. Fukaya, and D. E.
Bergles, “Vesicular release of glutamate from unmyelinated
axons in white matter,” Nature Neuroscience, vol. 10, no. 3, pp.
321–330, 2007.
[68] M. Kukley, E. Capetillo-Zarate, and D. Dietrich, “Vesicular
glutamate release from axons in white matter,” Nature Neuro-
science, vol. 10, no. 3, pp. 311–320, 2007.
[69] C. Li, L. Xiao, X. Liu et al., “A functional role of NMDA receptor
in regulating the differentiation of oligodendrocyte precursor
cells and remyelination,” Glia, vol. 61, no. 5, pp. 732–749, 2013.
[70] L. Xiao, C. Hu, W. Yang et al., “NMDA receptor couples Rac1-
GEF Tiam1 to direct oligodendrocyte precursor cell migration,”
Glia, vol. 61, no. 12, pp. 2078–2099, 2013.
[71] J.-M. Mangin and V. Gallo, “The curious case of NG2 cells:
transient trend or game changer?” ASN Neuro, vol. 3, no. 1,
Article ID e00052, 2011.
[72] J. Fannon, W. Tarmier, and D. Fulton, “Neuronal activity and
AMPA-type glutamate receptor activation regulates the mor-
phological development of oligodendrocyte precursor cells,”
Glia, vol. 63, no. 6, pp. 1021–1035, 2015.
[73] A. Sahel, F. C. Ortiz, C. Kerninon, P. P. Maldonado, M. C.
Angulo, andB.Nait-Oumesmar, “Alteration of synaptic connec-
tivity of oligodendrocyte precursor cells following demyelina-
tion,” Frontiers in Cellular Neuroscience, vol. 9, article 77, 2015.
[74] M. Velez-Fort, P. P. Maldonado, A. M. Butt, E. Audinat, and
M. C. Angulo, “Postnatal switch from synaptic to extrasynaptic
transmission between interneurons and NG2 cells,”The Journal
of Neuroscience, vol. 30, no. 20, pp. 6921–6929, 2010.
[75] S.-C. Lin and D. E. Bergles, “Synaptic signaling between
GABAergic interneurons and oligodendrocyte precursor cells
in the hippocampus,” Nature Neuroscience, vol. 7, no. 1, pp. 24–
32, 2004.
[76] A. Pastor, A. Chvatal, E. Sykova, and H. Kettenmann, “Glycine-
and GABA-activated currents in identified glial cells of the
developing rat spinal cord slice,” European Journal of Neuro-
science, vol. 7, no. 6, pp. 1188–1198, 1995.
[77] X. P. Tong, X. Y. Li, B. Zhou et al., “Ca2+ signaling evoked by
activation ofNa+ channels andNa+/Ca2+ exchangers is required
for GABA-induced NG2 cell migration,” The Journal of Cell
Biology, vol. 186, no. 1, pp. 113–128, 2009.
[78] N. Fro¨hlich, B. Nagy, A. Hovhannisyan, andM. Kukley, “Fate of
neuron-glia synapses during proliferation and differentiation of
NG2 cells,” Journal of Anatomy, vol. 219, no. 1, pp. 18–32, 2011.
[79] M. Zonouzi, J. Scafidi, P. Li et al., “GABAergic regulation of
cerebellar NG2 cell development is altered in perinatal white
matter injury,” Nature Neuroscience, vol. 18, no. 5, pp. 674–682,
2015.
[80] K. Luyt, T. P. Slade, J. J. Dorward et al., “Developing oligoden-
drocytes express functional GABA(B) receptors that stimulate
cell proliferation andmigration,” Journal of Neurochemistry, vol.
100, no. 3, pp. 822–840, 2007.
[81] B. Stevens, S. Porta, L. L. Haak, V. Gallo, and R. D. Fields,
“Adenosine: a neuron-glial transmitter promoting myelination
in the CNS in response to action potentials,”Neuron, vol. 36, no.
5, pp. 855–868, 2002.
[82] T. Othman, H. Yan, and S. A. Rivkees, “Oligodendrocytes
express functional A1 adenosine receptors that stimulate cellu-
lar migration,” Glia, vol. 44, no. 2, pp. 166–172, 2003.
[83] E. Coppi, L. Cellai, G. Maraula, A. M. Pugliese, and F. Pedata,
“Adenosine A2A receptors inhibit delayed rectifier potassium
currents and cell differentiation in primary purified oligoden-
drocyte cultures,”Neuropharmacology, vol. 73, pp. 301–310, 2013.
[84] E. Gonza´lez-Ferna´ndez, M. V. Sa´nchez-Go´mez, A. Pe´rez-
Samart´ın, R. O. Arellano, and C. Matute, “A3 adenosine recep-
tors mediate oligodendrocyte death and ischemic damage to
optic nerve,” Glia, vol. 62, no. 2, pp. 199–216, 2014.
[85] C. Agresti, M. E. Meomartini, S. Amadio et al., “ATP regulates
oligodendrocyte progenitor migration, proliferation, and dif-
ferentiation: involvement of metabotropic P2 receptors,” Brain
Research Reviews, vol. 48, no. 2, pp. 157–165, 2005.
[86] C. Matute, I. Torre, F. Pe´rez-Cerda´ et al., “P2X(7) receptor
blockade prevents ATP excitotoxicity in oligodendrocytes and
ameliorates experimental autoimmune encephalomyelitis,”The
Journal of Neuroscience, vol. 27, no. 35, pp. 9525–9533, 2007.
[87] L.-Y. Wang, W.-Q. Cai, P.-H. Chen, Q.-Y. Deng, and C.-M.
Zhao, “Downregulation of P2X
7
receptor expression in rat
oligodendrocyte precursor cells after hypoxia ischemia,” Glia,
vol. 57, no. 3, pp. 307–319, 2009.
[88] C. Agresti, M. E. Meomartini, S. Amadio et al., “Metabotropic
P2 receptor activation regulates oligodendrocyte progenitor
migration and development,” Glia, vol. 50, no. 2, pp. 132–144,
2005.
[89] J. T. Laitinen, A. Uri, G. Raidaru, and R. Miettinen,
“[(35)S]GTPgammaS autoradiography reveals a wide distribu-
tion of Gi/o-linked ADP receptors in the nervous system:
close similarities with the platelet P2YADP receptor,” Journal of
Neurochemistry, vol. 77, no. 2, pp. 505–518, 2001.
[90] S. Amadio, G. Tramini, A. Martorana et al., “Oligodendrocytes
express P2Y12 metabotropic receptor in adult rat brain,”Neuro-
science, vol. 141, no. 3, pp. 1171–1180, 2006.
[91] J. N. Larocca andG. Almazan, “Acetylcholine agonists stimulate
mitogen-activated protein kinase in oligodendrocyte progeni-
tors by muscarinic receptors,” Journal of Neuroscience Research,
vol. 50, no. 5, pp. 743–754, 1997.
[92] Q.-L. Cui, E. Fogle, and G. Almazan, “Muscarinic acetylcholine
receptors mediate oligodendrocyte progenitor survival through
Src-like tyrosine kinases and PI3K/Akt pathways,” Neurochem-
istry International, vol. 48, no. 5, pp. 383–393, 2006.
[93] F. De Angelis, A. Bernardo, V. Magnaghi, L. Minghetti, and
A. M. Tata, “Muscarinic receptor subtypes as potential targets
to modulate oligodendrocyte progenitor survival, proliferation,
16 BioMed Research International
and differentiation,” Developmental Neurobiology, vol. 72, no. 5,
pp. 713–728, 2012.
[94] K. Abiraman, S. U. Pol, M. A. O’Bara et al., “Anti-muscarinic
adjunct therapy accelerates functional human oligodendrocyte
repair,” Journal of Neuroscience, vol. 35, no. 8, pp. 3676–3688,
2015.
[95] M.Ve´lez-Fort, E. Audinat, andM.C. Angulo, “Functional alpha
7-containing nicotinic receptors of NG2-expressing cells in the
hippocampus,” Glia, vol. 57, no. 10, pp. 1104–1114, 2009.
[96] S. W. Rogers, N. Z. Gregori, N. Carlson, L. C. Gahring, and M.
Noble, “Neuronal nicotinic acetylcholine receptor expression by
O2A/Oligodendrocyte progenitor cells,” Glia, vol. 33, no. 4, pp.
306–313, 2001.
[97] R. A. Hill, K. D. Patel, J. Medved, A.M. Reiss, andA. Nishiyama,
“NG2 cells in white matter but not gray matter proliferate in
response to PDGF,” Journal of Neuroscience, vol. 33, no. 36, pp.
14558–14566, 2013.
[98] E. E. Frost, Z. Zhou, K. Krasnesky, and R. C. Armstrong,
“Initiation of oligodendrocyte progenitor cell migration by a
PDGF-A activated extracellular regulated kinase (ERK) signal-
ing pathway,”Neurochemical Research, vol. 34, no. 1, pp. 169–181,
2009.
[99] K. Azim, O. Raineteau, and A. M. Butt, “Intraventricular
injection of FGF-2 promotes generation of oligodendrocyte-
lineage cells in the postnatal and adult forebrain,” Glia, vol. 60,
no. 12, pp. 1977–1990, 2012.
[100] M. Furusho, A. J. Roulois, R. J. Franklin, and R. Bansal,
“Fibroblast growth factor signaling in oligodendrocyte-lineage
cells facilitates recovery of chronically demyelinated lesions but
is redundant in acute lesions,” Glia, 2015.
[101] J.-G. Hu, X.-J. Wu, Y.-F. Feng et al., “PDGF-AA and bFGF
mediate B104CM-induced proliferation of oligodendrocyte
precursor cells,” International Journal of Molecular Medicine,
vol. 30, no. 5, pp. 1113–1118, 2012.
[102] J. F. Talbott, Q. Cao, J. Bertram et al., “CNTF promotes
the survival and differentiation of adult spinal cord-derived
oligodendrocyte precursor cells in vitro but fails to promote
remyelination in vivo,” Experimental Neurology, vol. 204, no. 1,
pp. 485–489, 2007.
[103] J. Vernerey, M. Macchi, K. Magalon, M. Cayre, and P. Durbec,
“Ciliary neurotrophic factor controls progenitor migration
during remyelination in the adult rodent brain,”The Journal of
Neuroscience, vol. 33, no. 7, pp. 3240–3250, 2013.
[104] R. B. Tripathi andD.M.McTigue, “Chronically increased ciliary
neurotrophic factor and fibroblast growth factor-2 expression
after spinal contusion in rats,” Journal of Comparative Neurol-
ogy, vol. 510, no. 2, pp. 129–144, 2008.
[105] J. Xiao, A.W.Wong, M. M.Willingham,M. van den Buuse, T. J.
Kilpatrick, and S. S.Murray, “Brain-derived neurotrophic factor
promotes central nervous systemmyelination via a direct effect
upon oligodendrocytes,” NeuroSignals, vol. 18, no. 3, pp. 186–
202, 2010.
[106] A. W. Wong, J. Xiao, D. Kemper, T. J. Kilpatrick, and S. S.
Murray, “Oligodendroglial expression of TrkB independently
regulates myelination and progenitor cell proliferation,” The
Journal of Neuroscience, vol. 33, no. 11, pp. 4947–4957, 2013.
[107] B. A. Barres and M. C. Raff, “Control of oligodendrocyte
number in the developing rat optic nerve,” Neuron, vol. 12, no.
5, pp. 935–942, 1994.
[108] H.-T. Zhang, Z.-Y. Gao, Y.-Z. Chen, and T.-H.Wang, “Temporal
changes in the level of neurotrophins in the spinal cord and
associated precentral gyrus following spinal hemisection in
adult Rhesusmonkeys,” Journal of Chemical Neuroanatomy, vol.
36, no. 3-4, pp. 138–143, 2008.
[109] X.-L. Li, W. Zhang, X. Zhou et al., “Temporal changes in the
expression of some neurotrophins in spinal cord transected
adult rats,” Neuropeptides, vol. 41, no. 3, pp. 135–143, 2007.
[110] A. M. Thomas, S. K. Seidlits, A. G. Goodman et al., “Sonic
hedgehog and neurotrophin-3 increase oligodendrocyte num-
bers and myelination after spinal cord injury,” Integrative Biol-
ogy, vol. 6, no. 7, pp. 694–705, 2014.
[111] G. Banisadr, R.-D. Gosselin, P. Mechighel, W. Roste`ne, P.
Kitabgi, and S. M. Parsadaniantz, “Constitutive neuronal
expression of CCR2 chemokine receptor and its colocalization
with neurotransmitters in normal rat brain: functional effect
of MCP-1/CCL2 on calcium mobilization in primary cultured
neurons,” Journal of Comparative Neurology, vol. 492, no. 2, pp.
178–192, 2005.
[112] M. W. Adler, E. B. Geller, X. Chen, and T. J. Rogers, “Viewing
chemokines as a third major system of communication in the
brain,” AAPS Journal, vol. 7, no. 4, pp. E865–E870, 2005.
[113] X. Zhang, C. Chen, S. Ma, Y. Wang, X. Zhang, and X. Su,
“Inhibition of monocyte chemoattractant peptide-1 decreases
secondary spinal cord injury,”Molecular Medicine Reports, vol.
11, no. 6, pp. 4262–4266, 2015.
[114] L. Kadi, R. Selvaraju, P. de Lys, A. E. I. Proudfoot, T. N. C.
Wells, and U. Boschert, “Differential effects of chemokines on
oligodendrocyte precursor proliferation and myelin formation
in vitro,” Journal of Neuroimmunology, vol. 174, no. 1-2, pp. 133–
146, 2006.
[115] J. R. Patel, J. L. Williams, M. M. Muccigrosso et al., “Astrocyte
TNFR2 is required for CXCL12-mediated regulation of oligo-
dendrocyte progenitor proliferation and differentiation within
the adult CNS,” Acta Neuropathologica, vol. 124, no. 6, pp. 847–
860, 2012.
[116] G. Banisadr, T. J. Frederick, C. Freitag et al., “The role of CXCR4
signaling in the migration of transplanted oligodendrocyte
progenitors into the cerebral white matter,” Neurobiology of
Disease, vol. 44, no. 1, pp. 19–27, 2011.
[117] E. Tirotta, L. A. Kirby, M. N. Hatch, and T. E. Lane, “IFN-𝛾-
induced apoptosis of human embryonic stem cell derived oligo-
dendrocyte progenitor cells is restricted by CXCR2 signaling,”
Stem Cell Research, vol. 9, no. 3, pp. 208–217, 2012.
[118] E. Tirotta, R. M. Ransohoff, and T. E. Lane, “CXCR2 signaling
protects oligodendrocyte progenitor cells from IFN-𝛾/CXCL10-
mediated apoptosis,” Glia, vol. 59, no. 10, pp. 1518–1528, 2011.
[119] I. Pineau and S. Lacroix, “Proinflammatory cytokine synthesis
in the injured mouse spinal cord: multiphasic expression
pattern and identification of the cell types involved,” Journal of
Comparative Neurology, vol. 500, no. 2, pp. 267–285, 2007.
[120] T. Ishibashi, P. R. Lee, H. Baba, and R. D. Fields, “Leukemia
inhibitory factor regulates the timing of oligodendrocyte devel-
opment and myelination in the postnatal optic nerve,” Journal
of Neuroscience Research, vol. 87, no. 15, pp. 3343–3355, 2009.
[121] S. Rittchen, A. Boyd, A. Burns et al., “Myelin repair in vivo
is increased by targeting oligodendrocyte precursor cells with
nanoparticles encapsulating leukaemia inhibitory factor (LIF),”
Biomaterials, vol. 56, pp. 78–85, 2015.
BioMed Research International 17
[122] D.D. Rowe, L. A.Collier,H.A. Seifert et al., “Leukemia inhibitor
factor promotes functional recovery and oligodendrocyte sur-
vival in rat models of focal ischemia,” European Journal of
Neuroscience, vol. 40, no. 7, pp. 3111–3119, 2014.
[123] W. Pan and A. J. Kastin, “Cytokine transport across the injured
blood-spinal cord barrier,” Current Pharmaceutical Design, vol.
14, no. 16, pp. 1620–1624, 2008.
[124] L.-J. Chew, W. C. King, A. Kennedy, and V. Gallo, “Interferon-
gamma inhibits cell cycle exit in differentiating oligodendrocyte
progenitor cells,” Glia, vol. 52, no. 2, pp. 127–143, 2005.
[125] J. M. Rodgers, A. P. Robinson, E. S. Rosler et al., “IL-17A acti-
vates ERK1/2 and enhances differentiation of oligodendrocyte
progenitor cells,” Glia, vol. 63, no. 5, pp. 768–779, 2015.
[126] J. M. Vela, E. Molina-Holgado, A´. Are´valo-Mart´ın, G. Almaza´n,
and C. Guaza, “Interleukin-1 regulates proliferation and differ-
entiation of oligodendrocyte progenitor cells,” Molecular and
Cellular Neuroscience, vol. 20, no. 3, pp. 489–502, 2002.
[127] Q. R. Lu, D.-I. Yuk, J. A. Alberta et al., “Sonic hedgehog—
regulated oligodendrocyte lineage genes encoding bHLH pro-
teins in the mammalian central nervous system,” Neuron, vol.
25, no. 2, pp. 317–329, 2000.
[128] Q. Zhou, S. Wang, and D. J. Anderson, “Identification of a
novel family of oligodendrocyte lineage-specific basic helix-
loop-helix transcription factors,”Neuron, vol. 25, no. 2, pp. 331–
343, 2000.
[129] Q. Zhou and D. J. Anderson, “The bHLH transcription factors
OLIG2 and OLIG1 couple neuronal and glial subtype specifica-
tion,” Cell, vol. 109, no. 1, pp. 61–73, 2002.
[130] V. Balasubramaniyan, N. Timmer, B. Kust, E. Boddeke, and S.
Copray, “Transient expression of Olig1 initiates the differentia-
tion of neural stem cells into oligodendrocyte progenitor cells,”
Stem Cells, vol. 22, no. 6, pp. 878–882, 2004.
[131] C. L. Maire, A. Wegener, C. Kerninon, and B. N. Oumesmar,
“Gain-of-function of Olig transcription factors enhances oligo-
dendrogenesis and myelination,” Stem Cells, vol. 28, no. 9, pp.
1611–1622, 2010.
[132] S. Copray, V. Balasubramaniyan, J. Levenga, J. de Bruijn, R.
Liem, and E. Boddeke, “Olig2 overexpression induces the in
vitro differentiation of neural stem cells into mature oligoden-
drocytes,” Stem Cells, vol. 24, no. 4, pp. 1001–1010, 2006.
[133] Z. Liu, X. Hu, J. Cai et al., “Induction of oligodendrocyte
differentiation by Olig2 and Sox10: evidence for reciprocal
interactions and dosage-dependent mechanisms,”Developmen-
tal Biology, vol. 302, no. 2, pp. 683–693, 2007.
[134] A. Wegener, C. Deboux, C. Bachelin et al., “Gain of Olig2 func-
tion in oligodendrocyte progenitors promotes remyelination,”
Brain, vol. 138, no. 1, pp. 120–135, 2015.
[135] C. Zhang, G. Zhang, W. Rong, A. Wang, C. Wu, and X. Huo,
“Oscillating field stimulation promotes spinal cord remyelina-
tion by inducing differentiation of oligodendrocyte precursor
cells after spinal cord injury,” Bio-Medical Materials and Engi-
neering, vol. 24, no. 6, pp. 3629–3636, 2014.
[136] H. M. Kim, D. H. Hwang, J. Y. Choi et al., “Differential and
cooperative actions of Olig1 and Olig2 transcription factors on
immature proliferating cells after contusive spinal cord injury,”
Glia, vol. 59, no. 7, pp. 1094–1106, 2011.
[137] J. Paes de Faria, N. Kessaris, P. Andrew, W. D. Richardson, and
H. Li, “New Olig1 null mice confirm a non-essential role for
Olig1 in oligodendrocyte development,” BMCNeuroscience, vol.
15, article 12, 2014.
[138] X. Cheng, Y. Wang, Q. He, M. Qiu, S. R. Whittemore, and
Q. Cao, “Bone morphogenetic protein signaling and olig1/2
interact to regulate the differentiation and maturation of adult
oligodendrocyte precursor cells,” Stem Cells, vol. 25, no. 12, pp.
3204–3214, 2007.
[139] S.-Q. Huang, C.-L. Tang, S.-Q. Sun et al., “Demyelination ini-
tiated by oligodendrocyte apoptosis through enhancing endo-
plasmic reticulum-mitochondria interactions and Id2 expres-
sion after compressed spinal cord injury in rats,” CNS Neuro-
science andTherapeutics, vol. 20, no. 1, pp. 20–31, 2014.
[140] S. Huang, C. Tang, S. Sun et al., “Protective effect of elec-
troacupuncture on neural myelin sheaths is mediated via
promotion of oligodendrocyte proliferation and inhibition of
oligodendrocyte death after compressed spinal cord injury,”
Molecular Neurobiology, 2014.
[141] C. C. Stolt, A. Schlierf, P. Lommes et al., “SoxD proteins
influence multiple stages of oligodendrocyte development and
modulate SoxE protein function,” Developmental Cell, vol. 11,
no. 5, pp. 697–709, 2006.
[142] M. Finzsch, C. C. Stolt, P. Lommes, and M. Wegner, “Sox9
and Sox10 influence survival and migration of oligodendrocyte
precursors in the spinal cord by regulating PDGF receptor alpha
expression,” Development, vol. 135, no. 4, pp. 637–646, 2008.
[143] J. Hornig, F. Fro¨b, M. R. Vogl, I. Hermans-Borgmeyer, E.
R. Tamm, and M. Wegner, “The transcription factors Sox10
and Myrf define an essential regulatory network module in
differentiating oligodendrocytes,” PLoS Genetics, vol. 9, no. 10,
Article ID e1003907, 2013.
[144] M.Ku¨spert, A.Hammer,M. R. Bo¨sl, andM.Wegner, “Olig2 reg-
ulates Sox10 expression in oligodendrocyte precursors through
an evolutionary conserved distal enhancer,” Nucleic Acids
Research, vol. 39, no. 4, pp. 1280–1293, 2011.
[145] S.-Z. Wang, J. Dulin, H. Wu et al., “An oligodendrocyte-specific
zinc-finger transcription regulator cooperates with Olig2 to
promote oligodendrocyte differentiation,” Development, vol.
133, no. 17, pp. 3389–3398, 2006.
[146] J. R.Wrathall,W. Li, and L. D. Hudson, “Myelin gene expression
after experimental contusive spinal cord injury,”The Journal of
Neuroscience, vol. 18, no. 21, pp. 8780–8793, 1998.
[147] J. A. Nielsen, J. A. Berndt, L. D. Hudson, and R. C. Armstrong,
“Myelin transcription factor 1 (Myt1) modulates the prolif-
eration and differentiation of oligodendrocyte lineage cells,”
Molecular and Cellular Neuroscience, vol. 25, no. 1, pp. 111–123,
2004.
[148] M. Sugimori, M. Nagao, C.M. Parras et al., “Ascl1 is required for
oligodendrocyte development in the spinal cord,”Development,
vol. 135, no. 7, pp. 1271–1281, 2008.
[149] M. Wegner, “A matter of identity: transcriptional control in
oligodendrocytes,” Journal of Molecular Neuroscience, vol. 35,
no. 1, pp. 3–12, 2008.
[150] Y. He, J. Dupree, J. Wang et al., “The transcription factor Yin
Yang 1 is essential for oligodendrocyte progenitor differentia-
tion,” Neuron, vol. 55, no. 2, pp. 217–230, 2007.
[151] R. Tripathi and D. M. McTigue, “Prominent oligodendrocyte
genesis along the border of spinal contusion lesions,” Glia, vol.
55, no. 7, pp. 698–711, 2007.
18 BioMed Research International
[152] J. M. Lytle, R. Chittajallu, J. R. Wrathall, and V. Gallo, “NG2 cell
response in the CNP-EGFP mouse after contusive spinal cord
injury,” Glia, vol. 57, no. 3, pp. 270–285, 2009.
[153] Z. J. Chen, M. Negra, A. Levine, Y. Ughrin, and J. M. Levine,
“Oligodendrocyte precursor cells: reactive cells that inhibit
axon growth and regeneration,” Journal of Neurocytology, vol.
31, no. 6-7, pp. 481–495, 2002.
[154] D. M. McTigue, P. Wei, and B. T. Stokes, “Proliferation of
NG2-positive cells and altered oligodendrocyte numbers in the
contused rat spinal cord,” Journal of Neuroscience, vol. 21, no. 10,
pp. 3392–3400, 2001.
[155] K. Ishii, M. Toda, Y. Nakai et al., “Increase of oligodendrocyte
progenitor cells after spinal cord injury,” Journal of Neuroscience
Research, vol. 65, no. 6, pp. 500–507, 2001.
[156] L. J. Zai and J. R. Wrathall, “Cell proliferation and replacement
following contusive spinal cord injury,” Glia, vol. 50, no. 3, pp.
247–257, 2005.
[157] F. R. Sahinkaya, L. M. Milich, and D. M. McTigue, “Changes in
NG2 cells and oligodendrocytes in a new model of intraspinal
hemorrhage,” Experimental Neurology, vol. 255, pp. 113–126,
2014.
[158] G. Wolswijk and M. Noble, “Identification of an adult-specific
glial progenitor cell,” Development, vol. 105, no. 2, pp. 387–400,
1989.
[159] W. M. Carroll, A. R. Jennings, and L. J. Ironside, “Identification
of the adult resting progenitor cell by autoradiographic tracking
of oligodendrocyte precursors in experimental CNS demyelina-
tion,” Brain, vol. 121, no. 2, pp. 293–302, 1998.
[160] J. R. Siebert, D. J. Stelzner, and D. J. Osterhout, “Chondroitinase
treatment following spinal contusion injury increasesmigration
of oligodendrocyte progenitor cells,” Experimental Neurology,
vol. 231, no. 1, pp. 19–29, 2011.
[161] S. K. Ludwin and D. A. Bakker, “Can oligodendrocytes attached
to myelin proliferate?”The Journal of Neuroscience, vol. 8, no. 4,
pp. 1239–1244, 1988.
[162] H. S. Keirstead and W. F. Blakemore, “Identification of post-
mitotic oligodendrocytes incapable of remyelination within the
demyelinated adult spinal cord,” Journal of Neuropathology and
Experimental Neurology, vol. 56, no. 11, pp. 1191–1201, 1997.
[163] S. H. Kang, M. Fukaya, J. K. Yang, J. D. Rothstein, and D.
E. Bergles, “NG2+ CNS glial progenitors remain committed
to the oligodendrocyte lineage in postnatal life and following
neurodegeneration,” Neuron, vol. 68, no. 4, pp. 668–681, 2010.
[164] M.Watanabe, Y. Toyama, and A. Nishiyama, “Differentiation of
proliferated NG2-positive glial progenitor cells in a remyelinat-
ing lesion,” Journal of Neuroscience Research, vol. 69, no. 6, pp.
826–836, 2002.
[165] S. Lacroix, L. K. Hamilton, A. Vaugeois et al., “Central canal
ependymal cells proliferate extensively in response to traumatic
spinal cord injury but not demyelinating lesions,” PLoS ONE,
vol. 9, no. 1, Article ID e85916, 2014.
[166] F. Barnabe´-Heider, C. Go¨ritz, H. Sabelstro¨m et al., “Origin of
new glial cells in intact and injured adult spinal cord,” Cell Stem
Cell, vol. 7, no. 4, pp. 470–482, 2010.
[167] L. F. Corns, L. Atkinson, J. Daniel et al., “Cholinergic enhance-
ment of cell proliferation in the postnatal neurogenic niche of
the mammalian spinal cord,” Stem Cells, 2015.
[168] J. D. Guest, E. D. Hiester, and R. P. Bunge, “Demyelination
and Schwann cell responses adjacent to injury epicenter cavities
following chronic human spinal cord injury,” Experimental
Neurology, vol. 192, no. 2, pp. 384–393, 2005.
[169] J. M. Ruckh, J.-W. Zhao, J. L. Shadrach et al., “Rejuvenation of
regeneration in the aging central nervous system,” Cell Stem
Cell, vol. 10, no. 1, pp. 96–103, 2012.
[170] L. Sun, S. Liu, Q. Sun et al., “Inhibition of TROY promotes OPC
differentiation and increases therapeutic efficacy of OPC graft
for spinal cord injury,” Stem Cells and Development, vol. 23, no.
17, pp. 2104–2118, 2014.
[171] J. R. Plemel, S. B. Manesh, J. S. Sparling, and W. Tetzlaff,
“Myelin inhibits oligodendroglial maturation and regulates
oligodendrocytic transcription factor expression,” Glia, vol. 61,
no. 9, pp. 1471–1487, 2013.
[172] T. Kondo andM. C. Raff, “A role for Noggin in the development
of oligodendrocyte precursor cells,”Developmental Biology, vol.
267, no. 1, pp. 242–251, 2004.
[173] Q. Xiao, Y. Du, W. Wu, and H. K. Yip, “Bone morphogenetic
proteins mediate cellular response and, together with Nog-
gin, regulate astrocyte differentiation after spinal cord injury,”
Experimental Neurology, vol. 221, no. 2, pp. 353–366, 2010.
[174] J. K. Sabo, T. D. Aumann, D. Merlo, T. J. Kilpatrick, and H. S.
Cate, “Remyelination is altered by bone morphogenic protein
signaling in demyelinated lesions,” Journal of Neuroscience, vol.
31, no. 12, pp. 4504–4510, 2011.
[175] S. Jepson, B. Vought, C. H. Gross et al., “LINGO-1, a trans-
membrane signaling protein, inhibits oligodendrocyte differen-
tiation and myelination through intercellular self-interactions,”
The Journal of Biological Chemistry, vol. 287, no. 26, pp. 22184–
22195, 2012.
[176] J. L. Mason and J. E. Goldman, “A2B5+ and O4+ cycling
progenitors in the adult forebrain white matter respond dif-
ferentially to PDGF-AA, FGF-2, and IGF-1,” Molecular and
Cellular Neuroscience, vol. 20, no. 1, pp. 30–42, 2002.
[177] B. Ji, M. Li, W.-T. Wu et al., “LINGO-1 antagonist promotes
functional recovery and axonal sprouting after spinal cord
injury,” Molecular and Cellular Neuroscience, vol. 33, no. 3, pp.
311–320, 2006.
[178] Q.-L. Fu, B. Hu, X. Li et al., “LINGO-1 negatively regulates TrkB
phosphorylation after ocular hypertension,” European Journal
of Neuroscience, vol. 31, no. 6, pp. 1091–1097, 2010.
[179] Z. Su, Y. Yuan, J. Chen et al., “Reactive astrocytes inhibit the
survival and differentiation of oligodendrocyte precursor cells
by secreted TNF-𝛼,” Journal of Neurotrauma, vol. 28, no. 6, pp.
1089–1100, 2011.
[180] R. H. Woodruff, M. Fruttiger, W. D. Richardson, and R. J. M.
Franklin, “Platelet-derived growth factor regulates oligoden-
drocyte progenitor numbers in adult CNS and their response
following CNS demyelination,” Molecular and Cellular Neuro-
science, vol. 25, no. 2, pp. 252–262, 2004.
[181] W. Tetzlaff, E. B. Okon, S. Karimi-Abdolrezaee et al., “A
systematic review of cellular transplantation therapies for spinal
cord injury,” Journal of Neurotrauma, vol. 28, no. 8, pp. 1611–
1682, 2011.
[182] E. M. Medina-Rodr´ıguez, F. J. Arenzana, A. Bribia´n, and F.
de Castro, “Protocol to isolate a large amount of functional
oligodendrocyte precursor cells from the cerebral cortex of
BioMed Research International 19
adult mice and humans,” PLoS ONE, vol. 8, no. 11, Article ID
e81620, 2013.
[183] T. Deacon, J. Dinsmore, L. C. Costantini, J. Ratliff, and
O. Isacson, “Blastula-stage stem cells can differentiate into
dopaminergic and serotonergic neurons after transplantation,”
Experimental Neurology, vol. 149, no. 1, pp. 28–41, 1998.
[184] S. Kriks, J.-W. Shim, J. Piao et al., “Dopamine neurons derived
from human ES cells efficiently engraft in animal models of
Parkinson’s disease,”Nature, vol. 480, no. 7378, pp. 547–551, 2011.
[185] G. I. Nistor, M. O. Totoiu, N. Haque, M. K. Carpenter, and H.
S. Keirstead, “Human embryonic stem cells differentiate into
oligodendrocytes in high purity and myelinate after spinal cord
transplantation,” Glia, vol. 49, no. 3, pp. 385–396, 2005.
[186] N. Li, L. Tian, W. Wu et al., “Regional hypothermia inhibits
spinal cord somatosensory-evoked potentials without neural
damage in uninjured rats,” Journal of Neurotrauma, vol. 30, no.
15, pp. 1325–1333, 2013.
[187] K. Takahashi, K. Tanabe, M. Ohnuki et al., “Induction of
pluripotent stem cells from adult human fibroblasts by defined
factors,” Cell, vol. 131, no. 5, pp. 861–872, 2007.
[188] F. J. Najm, A. M. Lager, A. Zaremba et al., “Transcription
factor-mediated reprogramming of fibroblasts to expandable,
myelinogenic oligodendrocyte progenitor cells,”Nature Biotech-
nology, vol. 31, no. 5, pp. 426–433, 2013.
[189] H. Hentze, P. L. Soong, S. T. Wang, B. W. Phillips, T. C. Putti,
and N. R. Dunn, “Teratoma formation by human embryonic
stem cells: evaluation of essential parameters for future safety
studies,” Stem Cell Research, vol. 2, no. 3, pp. 198–210, 2009.
[190] T. Okarma, “Interview with Thomas Okarma, M.D., Ph.D.;
CEO, Geron,” Rejuvenation Research, vol. 12, no. 4, pp. 295–300,
2009.
[191] T. Yilmaz and E. Kaptanog˘lu, “Current and future medical
therapeutic strategies for the functional repair of spinal cord
injury,” World Journal of Orthopaedics, vol. 6, no. 1, pp. 42–55,
2015.
[192] R. P. Salewski, R. A. Mitchell, L. Li et al., “Transplantation
of induced pluripotent stem cell-derived neural stem cells
mediate functional recovery following thoracic spinal cord
injury through remyelination of axons,” StemCells Translational
Medicine, vol. 4, no. 7, pp. 743–754, 2015.
[193] S. Karimi-Abdolrezaee, D. Schut, J. Wang, and M. G. Fehlings,
“Chondroitinase and growth factors enhance activation and
oligodendrocyte differentiation of endogenous neural precur-
sor cells after spinal cord injury,” PLoS ONE, vol. 7, no. 5, Article
ID e37589, 2012.
[194] L. X. Zhang, Y. M. Yin, Z. Q. Zhang, and L. X. Deng, “Grafted
bone marrow stromal cells: a contributor to glial repair after
spinal cord injury,”TheNeuroscientist, vol. 21, no. 3, pp. 277–289,
2015.
[195] H. Gabr, W. A. El-Kheir, H. A. Farghali et al., “Intrathecal
transplantation of autologous adherent bone marrow cells
induces functional neurological recovery in a canine model of
spinal cord injury,” Cell Transplantation. In press.
[196] J. S. Sparling, F. Bretzner, J. Biernaskie et al., “Schwann cells
generated from neonatal skin-derived precursors or neonatal
peripheral nerve improve functional recovery after acute trans-
plantation into the partially injured cervical spinal cord of the
rat,” The Journal of Neuroscience, vol. 35, no. 17, pp. 6714–6730,
2015.
[197] H. Kanno, D. D. Pearse, H. Ozawa, E. Itoi, and M. B. Bunge,
“Schwann cell transplantation for spinal cord injury repair: its
significant therapeutic potential and prospectus,” Reviews in the
Neurosciences, vol. 26, no. 2, pp. 121–128, 2015.
[198] K. Iwatsuki, T. Yoshimine, H. Kishima et al., “Transplantation
of olfactory mucosa following spinal cord injury promotes
recovery in rats,” NeuroReport, vol. 19, no. 13, pp. 1249–1252,
2008.
[199] J. Lu, F. Fe´ron, A. Mackay-Sim, and P. M. E. Waite, “Olfactory
ensheathing cells promote locomotor recovery after delayed
transplantation into transected spinal cord,” Brain, vol. 125, no.
1, pp. 14–21, 2002.
[200] C. Lima, J. Pratas-Vital, P. Escada, A. Hasse-Ferreira, C. Capu-
cho, and J. D. Peduzzi, “Olfactory mucosa autografts in human
spinal cord injury: a pilot clinical study,” Journal of Spinal Cord
Medicine, vol. 29, no. 3, pp. 191–203, 2006.
[201] Y. Rao, W. Zhu, Y. Guo et al., “Long-term outcome of olfactory
ensheathing cell transplantation in six patients with chronic
complete spinal cord injury,” Cell Transplantation, vol. 22,
supplement 1, pp. S21–S25, 2013.
[202] Z. C. Zheng, G. F. Liu, Y. X. Chen, and S. G. Wei, “Olfactory
ensheathing cell transplantation improves sympathetic skin
responses in chronic spinal cord injury,” Neural Regeneration
Research, vol. 8, no. 30, pp. 2849–2855, 2013.
[203] S. Wang, J. Lu, Y. A. Li et al., “Autologous olfactory lamina
propria transplantation for chronic spinal cord injury: three-
year follow-up outcomes from a prospective double blinded
clinical trial,” Cell Transplantation. In press.
[204] J. R. Faulkner, J. E. Herrmann, M. J. Woo, K. E. Tansey, N. B.
Doan, and M. V. Sofroniew, “Reactive astrocytes protect tissue
and preserve function after spinal cord injury,” The Journal of
Neuroscience, vol. 24, no. 9, pp. 2143–2155, 2004.
[205] C. Schachtrup, J. K. Ryu, M. J. Helmrick et al., “Fibrinogen
triggers astrocyte scar formation by promoting the availability
of active TGF-beta after vascular damage,” The Journal of
Neuroscience, vol. 30, no. 17, pp. 5843–5854, 2010.
[206] I. B. Wanner, M. A. Anderson, B. Song et al., “Glial scar borders
are formed by newly proliferated, elongated astrocytes that
interact to corral inflammatory and fibrotic cells via STAT3-
dependent mechanisms after spinal cord injury,” Journal of
Neuroscience, vol. 33, no. 31, pp. 12870–12886, 2013.
[207] S. Hermanns, N. Klapka, and H. W. Mu¨ller, “The collagenous
lesion scar—an obstacle for axonal regeneration in brain and
spinal cord injury,” Restorative Neurology and Neuroscience, vol.
19, no. 1-2, pp. 139–148, 2001.
[208] A. Rolls, R. Shechter, and M. Schwartz, “The bright side of the
glial scar in CNS repair,” Nature Reviews Neuroscience, vol. 10,
no. 3, pp. 235–241, 2009.
[209] J. W. Fawcett, “Overcoming inhibition in the damaged spinal
cord,” Journal of Neurotrauma, vol. 23, no. 3-4, pp. 371–383,
2006.
[210] A. Rasouli, N. Bhatia, P. Dinh, K. Cahill, S. Suryadevara, and
R. Gupta, “Resection of glial scar following spinal cord injury,”
Journal of Orthopaedic Research, vol. 27, no. 7, pp. 931–936, 2009.
[211] J.W. Fawcett andR.A.Asher, “The glial scar and central nervous
system repair,” Brain Research Bulletin, vol. 49, no. 6, pp. 377–
391, 1999.
20 BioMed Research International
[212] T. Laabs, D. Carulli, H. M. Geller, and J. W. Fawcett, “Chon-
droitin sulfate proteoglycans in neural development and regen-
eration,” Current Opinion in Neurobiology, vol. 15, no. 1, pp. 116–
120, 2005.
[213] J. R. Siebert, A. C. Steencken, and D. J. Osterhout, “Chondroitin
sulfate proteoglycans in the nervous system: inhibitors to
repair,” BioMed Research International, vol. 2014, Article ID
845323, 15 pages, 2014.
[214] Z. J. Chen, Y. Ughrin, and J. M. Levine, “Inhibition of axon
growth by oligodendrocyte precursor cells,” Molecular and
Cellular Neuroscience, vol. 20, no. 1, pp. 125–139, 2002.
[215] Y. M. Ughrin, Z. J. Chen, and J. M. Levine, “Multiple regions
of the NG2 proteoglycan inhibit neurite growth and induce
growth cone collapse,” Journal of Neuroscience, vol. 23, no. 1, pp.
175–186, 2003.
[216] R. de Castro Jr., R. Tajrishi, J. Claros, and W. B. Stallcup,
“Differential responses of spinal axons to transection: influence
of the NG2 proteoglycan,” Experimental Neurology, vol. 192, no.
2, pp. 299–309, 2005.
[217] A. M. Tan, M. Colletti, A. T. Rorai, J. H. P. Skene, and J. M.
Levine, “Antibodies against the NG2 proteoglycan promote the
regeneration of sensory axons within the dorsal columns of the
spinal cord,” Journal of Neuroscience, vol. 26, no. 18, pp. 4729–
4739, 2006.
[218] I. Novotna, L. Slovinska, I. Vanicky, M. Cizek, J. Radonak,
and D. Cizkova, “IT delivery of ChABC modulates NG2 and
promotes GAP-43 axonal regrowth after spinal cord injury,”
Cellular andMolecularNeurobiology, vol. 31, no. 8, pp. 1129–1139,
2014.
[219] H. A. Petrosyan, A. S. Hunanyan, V. Alessi, L. Schnell, J. Levine,
and V. L. Arvanian, “Neutralization of inhibitory molecule
NG2 improves synaptic transmission, retrograde transport, and
locomotor function after spinal cord injury in adult rats,” The
Journal of Neuroscience, vol. 33, no. 9, pp. 4032–4043, 2013.
[220] J. R. Siebert and D. J. Osterhout, “The inhibitory effects of
chondroitin sulfate proteoglycans on oligodendrocytes,” Journal
of Neurochemistry, vol. 119, no. 1, pp. 176–188, 2011.
[221] S. A. Busch and J. Silver, “The role of extracellularmatrix inCNS
regeneration,”Current Opinion inNeurobiology, vol. 17, no. 1, pp.
120–127, 2007.
[222] J. C. Pendleton, M. J. Shamblott, D. S. Gary et al., “Chon-
droitin sulfate proteoglycans inhibit oligodendrocyte myelina-
tion through PTPsigma,” Experimental Neurology, vol. 247, pp.
113–121, 2013.
[223] A. L. Hawthorne, H. Hu, B. Kundu et al., “The unusual response
of serotonergic neurons after CNS injury: lack of axonal dieback
and enhanced sprouting within the inhibitory environment of
the glial scar,” Journal of Neuroscience, vol. 31, no. 15, pp. 5605–
5616, 2011.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
